

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAPEZ1617

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 15 CAOLD to be discontinued on December 31, 2008
NEWS 3 OCT 07 EPFULL enhanced with full implementation of EPC2000
NEWS 4 OCT 07 Multiple databases enhanced for more flexible patent
number searching
NEWS 5 OCT 22 Current-awareness alert (SDI) setup and editing
enhanced
NEWS 6 OCT 22 WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT
Applications
NEWS 7 OCT 24 CHEMLIST enhanced with intermediate list of
pre-registered REACH substances
NEWS 8 NOV 21 CAS patent coverage to include exemplified prophetic
substances identified in English-, French-, German-,
and Japanese-language basic patents from 2004-present
NEWS 9 NOV 26 MARPAT enhanced with FSORT command
NEWS 10 NOV 26 MEDLINE year-end processing temporarily halts
availability of new fully-indexed citations
NEWS 11 NOV 26 CHEMSAFE now available on STN Easy
NEWS 12 NOV 26 Two new SET commands increase convenience of STN
searching
NEWS 13 DEC 01 ChemPort single article sales feature unavailable
NEWS 14 DEC 12 GBFULL now offers single source for full-text
coverage of complete UK patent families
NEWS 15 DEC 17 Fifty-one pharmaceutical ingredients added to PS
NEWS 16 JAN 06 The retention policy for unread STNmail messages
will change in 2009 for STN-Columbus and STN-Tokyo

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 09:58:41 ON 07 JAN 2009

=> file reg
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.22	0.22

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 09:59:07 ON 07 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 6 JAN 2009 HIGHEST RN 1092767-60-6
DICTIONARY FILE UPDATES: 6 JAN 2009 HIGHEST RN 1092767-60-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\STNEXP\Queries\10590724 elected.str



chain nodes :

7 8 10 11 12 18 25 26 27 28 29

ring nodes :

1 2 3 4 5 6 9 13 14 15 16 17 19 20 21 22 23 24

chain bonds :

3-10 5-7 6-11 7-8 8-9 8-29 11-12 16-18 18-19 21-25 25-26 25-28 26-27

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 9-13 9-17 13-14 14-15 15-16 16-17 19-20 19-24
20-21 21-22 22-23 23-24

exact/norm bonds :

5-7 6-11 7-8 8-29 11-12 16-18 18-19 25-26 25-28 26-27
 exact bonds :
 3-10 8-9 21-25
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 9-13 9-17 13-14 14-15 15-16 16-17 19-20 19-24
 20-21 21-22 22-23 23-24

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:CLASS
 11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:Atom
 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:CLASS 26:CLASS 27:CLASS 28:CLASS
 29:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using SIN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 09:59:56 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 24 TO ITERATE

100.0% PROCESSED 24 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**

PROJECTED ITERATIONS: 187 TO 773

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s ll sss ful
FULL SEARCH INITIATED 10:00:00 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 377 TO ITERATE

100.0% PROCESSED 377 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L3 1 SEA SSS FUL L1

=> fil cap
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 186.36 186.58

FILE 'CAPLUS' ENTERED AT 10:00:06 ON 07 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Jan 2009 VOL 150 ISS 2
FILE LAST UPDATED: 6 Jan 2009 (20090106/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l3

L4 1 L3

=> d l4

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:982303 CAPLUS
DN 143:286291
TI Preparation of 2-pyridinecarboxamides as kinase inhibitors
IN Burgorf, Lars; Buchstaller, Hans-Peter; Stieber, Frank; Amendt, Christiane; Greiner, Hartmut; Grell, Matthias; Sirrenberg, Christian; Zenke, Frank
PA Merck Patent G.m.b.H., Germany
SO Ger. Offen., 33 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 102004009238	A1	20050908	DE 2004-102004009238	20040226

AU 2005219496	A1	20050915	AU 2005-219496	20050113
CA 2557302	A1	20050915	CA 2005-2557302	20050113
WO 2005085202	A1	20050915	WO 2005-EP273	20050113

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1718614	A1	20061108	EP 2005-700886	20050113
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
JP 2007523921	T	20070823	JP 2007-500077	20050113
US 20070142440	A1	20070621	US 2006-590724	20060825

PRAI DE 2004-102004009238 A 20040226

WO 2005-EP273 W 20050113

OS MARPAT 143:286291

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

3.75

190.33

STN INTERNATIONAL LOGOFF AT 10:03:22 ON 07 JAN 2009

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAPEZ1617

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1	Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 15 CAOLD to be discontinued on December 31, 2008
NEWS 3	OCT 07 EPFULL enhanced with full implementation of EPC2000
NEWS 4	OCT 07 Multiple databases enhanced for more flexible patent number searching
NEWS 5	OCT 22 Current-awareness alert (SDI) setup and editing enhanced
NEWS 6	OCT 22 WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications
NEWS 7	OCT 24 CHEMLIST enhanced with intermediate list of pre-registered REACH substances
NEWS 8	NOV 21 CAS patent coverage to include exemplified prophetic

substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present

NEWS 9 NOV 26 MARPAT enhanced with FSORT command

NEWS 10 NOV 26 MEDLINE year-end processing temporarily halts availability of new fully-indexed citations

NEWS 11 NOV 26 CHEMSAFE now available on STN Easy

NEWS 12 NOV 26 Two new SET commands increase convenience of STN searching

NEWS 13 DEC 01 ChemPort single article sales feature unavailable

NEWS 14 DEC 12 GBFULL now offers single source for full-text coverage of complete UK patent families

NEWS 15 DEC 17 Fifty-one pharmaceutical ingredients added to PS

NEWS 16 JAN 06 The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:08:00 ON 07 JAN 2009

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 12:08:26 ON 07 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 JAN 2009 HIGHEST RN 1092767-60-6
DICTIONARY FILE UPDATES: 6 JAN 2009 HIGHEST RN 1092767-60-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10590724 generic.str



```
chain nodes :
7 8 15 22
ring nodes :
1 2 3 4 5 6 9 10 11 12 13 14 16 17 18 19 20 21
chain bonds :
5-7 7-8 8-9 8-22 13-15 15-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14 16-17 16-21
17-18 18-19 19-20 20-21
exact/norm bonds :
5-7 7-8 8-9 8-22 13-15 15-16 16-17 16-21 17-18 18-19 19-20 20-21
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14
```

G1:C,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 12:08:53 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 7339 TO ITERATE

27.3% PROCESSED 2000 ITERATIONS

32 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 141644 TO 151916

PROJECTED ANSWERS: 1698 TO 2998

L2 32 SEA SSS SAM L1

=> s l1 sss ful

FULL SEARCH INITIATED 12:08:58 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 145218 TO ITERATE

100.0% PROCESSED 145218 ITERATIONS

2881 ANSWERS

SEARCH TIME: 00.00.04

L3 2881 SEA SSS FUL L1

=> fil cap

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

185.88

186.10

FILE 'CAPLUS' ENTERED AT 12:09:10 ON 07 JAN 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Jan 2009 VOL 150 ISS 2
FILE LAST UPDATED: 6 Jan 2009 (20090106/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

```
=> s l3
L4      654 L3

=> s l4 and (py<2004 or ay<2004 or pry<2004)
      24034085 PY<2004
      4792818 AY<2004
      4264480 PRY<2004
L5      589 L4 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> s l5 and kinase inhibitor
      338645 KINASE
      63420 KINASES
      348962 KINASE
           (KINASE OR KINASES)
      601221 INHIBITOR
      593432 INHIBITORS
      931623 INHIBITOR
           (INHIBITOR OR INHIBITORS)
      45689 KINASE INHIBITOR
           (KINASE(W) INHIBITOR)
L6      27 L5 AND KINASE INHIBITOR

=> d scan

L6      27 ANSWERS  CAPLUS  COPYRIGHT 2009 ACS on STN
CC      28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
      Section cross-reference(s): 1, 63
TI      Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
ST      pyrazolopyrimidine prepn cyclin dependent kinase inhibitor CDK2 GSK3beta
      MAPK; antitumor pyrazolopyrimidine prepn
IT      Lymphoma
           (Burkett's; preparation of pyrazolopyrimidines as cyclin-dependent kinase
           inhibitors)
IT      Sarcoma
           (Kaposi's; preparation of pyrazolopyrimidines as cyclin-dependent kinase
           inhibitors)
IT      Neuroglia, neoplasm
           (astrocytoma; preparation of pyrazolopyrimidines as cyclin-dependent kinase
           inhibitors)
IT      Antibodies and Immunoglobulins
      RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
           (co-administration with antibodies to EGFR; preparation of
           pyrazolopyrimidines as cyclin-dependent kinase inhibitors)
IT      Cytotoxic agents
           (co-administration; preparation of pyrazolopyrimidines as cyclin-dependent
           kinase inhibitors)
```

IT Intestine, neoplasm
(colon; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT Macrolides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(epothilones, co-administration; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT Sarcoma
(fibrosarcoma; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT Thyroid gland, neoplasm
(follicle cell; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT Neoplasm
(head and neck, treating; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT Genetic element
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(intron, co-administration; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT Skin, neoplasm
(keratoacanthoma; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT B-cell lymphoma
(mantle cell lymphoma, treating; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT Astrocyte
(neoplasm, astrocytoma; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT Schwann cell
(neoplasm, schwannoma; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT Nerve, neoplasm
(neuroblastoma; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT Bone, neoplasm
Sarcoma
(osteosarcoma; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT Acute myeloid leukemia
Acute promyelocytic leukemia
Antitumor agents
B-cell lymphoma
Bladder, neoplasm
Cervix, neoplasm
Chronic myeloid leukemia
Combination chemotherapy
Esophagus, neoplasm
Gallbladder, neoplasm
Hodgkin's disease
Human
Kidney, neoplasm
Leukemia
Liver, neoplasm
Lung, neoplasm
Mammary gland, neoplasm
Melanoma
Myelodysplastic syndromes
Neuroglia, neoplasm
Non-Hodgkin lymphoma
Ovary, neoplasm
Pancreas, neoplasm

Prostate gland, neoplasm
 Skin, neoplasm
 Small-cell lung carcinoma
 Stomach, neoplasm
 T-cell lymphoma
 Thyroid gland, neoplasm
 (preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT Sarcoma
 (rhabdomyosarcoma; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT Nervous system, neoplasm
 (schwannoma; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT Testis, neoplasm
 (seminoma; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT Carcinoma
 (squamous cell; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT Carcinoma
 (teratocarcinoma; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT Head and Neck, neoplasm
 Multiple myeloma
 Neoplasm
 Non-small-cell lung carcinoma
 (treating; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT Acute lymphocytic leukemia
 (treatment of acute lymphocytic leukemia and acute lymphoblastic leukemia; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT Skin, disease
 (xeroderma pigmentosum, treating; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT 50-07-7 50-18-0 50-24-8 50-44-2 50-76-0, Actinomycin D 50-91-9
 51-18-3 51-21-8 51-75-2 53-03-2 53-19-0 54-91-1 55-98-1
 56-53-1 57-22-7 57-63-6 58-18-4 58-22-0 66-75-1 68-96-2
 71-58-9 76-43-7 83-43-2 124-94-7 125-84-8 127-07-1 147-94-4
 148-82-3 154-42-7 154-93-8 305-03-3 521-12-0 569-57-3 595-33-5
 645-05-6 671-16-9 865-21-4, Vincalukoblastine 968-93-4 2998-57-4
 3778-73-2 4342-03-4 9015-68-3, Asparaginase 10540-29-1 11056-06-7
 Bleomycin 13010-47-4 13311-84-7 14769-73-4 15663-27-1 18378-89-7
 18883-66-4 20830-81-3 23214-92-8 25316-40-9 29767-20-2
 33069-62-4 33419-42-0 41575-94-4 51264-14-3 53643-48-4
 53714-56-0 53910-25-1 56420-45-2 58957-92-9 61825-94-3
 65271-80-9 65807-02-5 75607-67-9 85622-93-1 89778-26-7
 95058-81-4 97682-44-5 114977-28-5 123948-87-8 154361-50-9
 183319-69-9 184475-35-2 192185-68-5 193275-84-2 195987-41-8
 220127-57-1 253863-00-2

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (co-administration; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT 142805-58-1
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (mapk/erk kinase; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT 141349-86-2 143375-65-9 443900-95-6
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT 672322-42-8P 779353-95-6P 934342-90-2P 1008793-86-9P 1008793-87-0P
 RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic)

preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT	672315-17-2P	672315-22-9P	672315-47-8P	672315-98-9P	672316-00-6P
	672316-20-0P	672316-21-1P	672316-22-2P	672316-23-3P	672316-24-4P
	672316-47-1P	672316-48-2P	672316-49-3P	672316-50-6P	672316-51-7P
	672316-53-9P	672316-54-0P	672316-56-2P	672316-58-4P	672316-59-5P
	672316-61-9P	672316-63-1P	672316-64-2P	672316-65-3P	672316-67-5P
	672317-02-1P	672317-21-4P	672317-23-6P	672317-24-7P	672317-26-9P
	672317-27-0P	672317-29-2P	672317-30-5P	672317-34-9P	672317-36-1P
	672317-38-3P	672317-40-7P	672317-41-8P	672317-75-8P	672317-77-0P
	672317-82-7P	672317-97-4P	672318-41-1P	672318-77-3P	672318-99-9P
	672319-13-0P	672319-14-1P	672319-19-6P	672319-26-5P	672319-95-8P
	672320-02-4P	672320-04-6P	672321-14-1P	672321-36-7P	672321-41-4P
	672321-43-6P	672321-49-2P	672321-50-5P	672321-58-3P	672321-62-9P
	672322-21-3P	672322-25-7P	672322-30-4P	672322-31-5P	672322-32-6P
	672322-34-8P	672322-36-0P	672322-38-2P	672322-39-3P	672322-40-6P
	672322-41-7P	672323-76-1P			

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT	672314-94-2P	672314-95-3P	672314-96-4P	672314-97-5P	672314-98-6P
	672314-99-7P	672315-00-3P	672315-01-4P	672315-02-5P	672315-03-6P
	672315-04-7P	672315-05-8P	672315-06-9P	672315-07-0P	672315-08-1P
	672315-09-2P	672315-10-5P	672315-11-6P	672315-12-7P	672315-13-8P
	672315-14-9P	672315-15-0P	672315-16-1P	672315-18-3P	672315-19-4P
	672315-20-7P	672315-21-8P	672315-23-0P	672315-24-1P	672315-25-2P
	672315-26-3P	672315-27-4P	672315-28-5P	672315-29-6P	672315-30-9P
	672315-31-0P	672315-32-1P	672315-33-2P	672315-34-3P	672315-35-4P
	672315-36-5P	672315-37-6P	672315-38-7P	672315-39-8P	672315-40-1P
	672315-42-3P	672315-44-5P	672315-45-6P	672315-46-7P	672315-48-9P
	672315-49-0P	672315-50-3P	672315-51-4P	672315-52-5P	672315-53-6P
	672315-54-7P	672315-55-8P	672315-56-9P	672315-57-0P	672315-58-1P
	672315-59-2P	672315-60-5P	672315-61-6P	672315-62-7P	672315-63-8P
	672315-64-9P	672315-65-0P	672315-66-1P	672315-67-2P	672315-68-3P
	672315-69-4P	672315-70-7P	672315-71-8P	672315-72-9P	672315-73-0P
	672315-74-1P	672315-75-2P	672315-76-3P	672315-77-4P	672315-78-5P
	672315-79-6P	672315-80-9P	672315-81-0P	672315-82-1P	672315-83-2P
	672315-84-3P	672315-85-4P	672315-86-5P	672315-87-6P	672315-88-7P
	672315-89-8P	672315-90-1P	672315-91-2P	672315-92-3P	672315-93-4P
	672315-94-5P	672315-95-6P	672315-96-7P	672315-97-8P	672315-99-0P
	672316-01-7P	672316-02-8P	672316-03-9P	672316-04-0P	672316-05-1P
	672316-06-2P	672316-07-3P	672316-08-4P	672316-09-5P	672316-10-8P
	672316-11-9P	672316-12-0P	672316-13-1P	672316-14-2P	672316-15-3P
	672316-16-4P	672316-17-5P	672316-18-6P	672316-19-7P	672316-25-5P
	672316-26-6P	672316-27-7P	672316-28-8P	672316-29-9P	672316-30-2P
	672316-31-3P	672316-32-4P	672316-33-5P	672316-34-6P	672316-35-7P
	672316-36-8P	672316-37-9P	672316-38-0P	672316-39-1P	672316-40-4P
	672316-41-5P	672316-42-6P	672316-43-7P	672316-44-8P	672316-45-9P
	672316-46-0P	672316-68-6P	672316-69-7P	672316-71-1P	672316-73-3P
	672316-75-5P	672316-77-7P	672316-79-9P	672316-80-2P	672316-81-3P
	672316-83-5P	672316-84-6P	672316-86-8P	672316-90-4P	672316-92-6P
	672316-93-7P	672316-95-9P	672316-98-2P	672317-00-9P	672317-04-3P
	672317-06-5P	672317-08-7P	672317-10-1P	672317-12-3P	672317-14-5P
	672317-15-6P	672317-16-7P	672317-17-8P	672317-19-0P	672317-31-6P
	672317-33-8P	672317-43-0P	672317-45-2P	672317-47-4P	672317-49-6P
	672317-50-9P	672317-51-0P	672317-52-1P	672317-54-3P	672317-56-5P
	672317-57-6P	672317-58-7P	672317-60-1P	672317-62-3P	672317-64-5P
	672317-66-7P	672317-68-9P	672317-70-3P	672317-71-4P	672317-72-5P
	672317-74-7P	672317-79-2P	672317-80-5P	672317-83-8P	672317-85-0P
	672317-86-1P	672317-88-3P	672317-90-7P	672317-91-8P	672317-93-0P

672317-95-2P	672317-99-6P	672318-00-2P	672318-02-4P	672318-03-5P
672318-04-6P	672318-05-7P	672318-07-9P	672318-08-0P	672318-10-4P
672318-11-5P	672318-13-7P	672318-15-9P	672318-17-1P	672318-20-6P
672318-22-8P	672318-24-0P	672318-26-2P	672318-28-4P	672318-30-8P
672318-31-9P	672318-32-0P	672318-33-1P	672318-35-3P	672318-37-5P
672318-39-7P	672318-40-0P	672318-43-3P	672318-45-5P	672318-47-7P
672318-49-9P	672318-51-3P	672318-53-5P	672318-54-6P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

IT	(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)			
672318-56-8P	672318-58-0P	672318-60-4P	672318-61-5P	672318-63-7P
672318-64-8P	672318-66-0P	672318-68-2P	672318-70-6P	672318-72-8P
672318-74-0P	672318-76-2P	672318-79-5P	672318-81-9P	672318-82-0P
672318-84-2P	672318-85-3P	672318-87-5P	672318-88-6P	672318-90-0P
672318-92-2P	672318-94-4P	672318-95-5P	672318-97-7P	672319-01-6P
672319-03-8P	672319-05-0P	672319-07-2P	672319-09-4P	672319-11-8P
672319-15-2P	672319-17-4P	672319-18-5P	672319-21-0P	672319-23-2P
672319-25-4P	672319-28-7P	672319-30-1P	672319-32-3P	672319-34-5P
672319-35-6P	672319-37-8P	672319-39-0P	672319-40-3P	672319-42-5P
672319-44-7P	672319-46-9P	672319-48-1P	672319-49-2P	672319-51-6P
672319-53-8P	672319-54-9P	672319-55-0P	672319-56-1P	672319-58-3P
672319-60-7P	672319-62-9P	672319-64-1P	672319-66-3P	672319-67-4P
672319-69-6P	672319-71-0P	672319-73-2P	672319-76-5P	672319-77-6P
672319-78-7P	672319-80-1P	672319-82-3P	672319-84-5P	672319-86-7P
672319-88-9P	672319-89-0P	672319-90-3P	672319-91-4P	672319-93-6P
672319-97-0P	672320-00-2P	672320-06-8P	672320-08-0P	672320-10-4P
672320-11-5P	672320-12-6P	672320-14-8P	672320-16-0P	672320-18-2P
672320-20-6P	672320-22-8P	672320-24-0P	672320-26-2P	672320-27-3P
672320-28-4P	672320-29-5P	672320-32-0P	672320-33-1P	672320-35-3P
672320-37-5P	672320-39-7P	672320-40-0P	672320-41-1P	672320-43-3P
672320-45-5P	672320-47-7P	672320-48-8P	672320-50-2P	672320-51-3P
672320-53-5P	672320-55-7P	672320-56-8P	672320-57-9P	672320-59-1P
672320-61-5P	672320-63-7P	672320-65-9P	672320-66-0P	672320-67-1P
672320-69-3P	672320-71-7P	672320-73-9P	672320-75-1P	672320-76-2P
672320-78-4P	672320-80-8P	672320-82-0P	672320-84-2P	672320-85-3P
672320-87-5P	672320-89-7P	672320-91-1P	672320-92-2P	672320-94-4P
672320-96-6P	672320-98-8P	672320-99-9P	672321-00-5P	672321-01-6P
672321-03-8P	672321-04-9P	672321-05-0P	672321-07-2P	672321-09-4P
672321-11-8P	672321-12-9P	672321-16-3P	672321-17-4P	672321-19-6P
672321-21-0P	672321-23-2P	672321-25-4P	672321-26-5P	672321-28-7P
672321-29-8P	672321-30-1P	672321-32-3P	672321-34-5P	672321-38-9P
672321-39-0P	672321-45-8P	672321-46-9P	672321-47-0P	672321-52-7P
672321-54-9P	672321-56-1P	672321-60-7P	672321-64-1P	672321-65-2P
672321-66-3P	672321-67-4P	672321-69-6P	672321-71-0P	672321-72-1P
672321-74-3P	672321-76-5P	672321-78-7P	672321-80-1P	672321-82-3P
672321-83-4P	672321-85-6P	672321-87-8P	672321-88-9P	672321-90-3P
672321-92-5P	672321-93-6P	672321-95-8P	672321-97-0P	672321-99-2P
672322-00-8P	672322-02-0P	672322-04-2P	672322-05-3P	672322-07-5P
672322-09-7P	672322-10-0P	672322-12-2P	672322-14-4P	672322-16-6P
672322-17-7P	672322-19-9P	672322-20-2P	672322-23-5P	672322-27-9P
672322-29-1P	672322-44-0P	672322-46-2P	672322-48-4P	672322-50-8P
672322-52-0P	672322-53-1P	672322-54-2P	672322-55-3P	672322-57-5P
672322-59-7P	672322-61-1P	672322-62-2P	672322-64-4P	672322-66-6P
672322-68-8P	672322-70-2P	672322-72-4P	672322-73-5P	672322-74-6P
672322-75-7P	672322-76-8P	672322-78-0P	672322-80-4P	672322-82-6P
672322-83-7P	672322-85-9P	672322-87-1P	672322-89-3P	672322-91-7P
672322-93-9P	672322-94-0P	672322-95-1P	672322-96-2P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT	672322-98-4P	672323-00-1P	672323-02-3P	672323-04-5P	677782-53-5P
	677782-54-6P	677782-55-7P	677782-56-8P	677782-57-9P	677782-58-0P
	677782-59-1P	677782-60-4P	677782-61-5P	677782-62-6P	677782-63-7P
	677782-64-8P	677782-65-9P	677782-66-0P	677782-67-1P	677782-68-2P
	677782-69-3P	677782-70-6P	677782-71-7P	677782-72-8P	677782-73-9P
	677782-74-0P	677782-75-1P	677782-76-2P	677782-77-3P	677782-78-4P
	677782-79-5P	677782-80-8P	677782-81-9P	677782-82-0P	677782-83-1P
	677782-84-2P	677782-85-3P	677782-86-4P	677782-87-5P	677782-88-6P
	677782-89-7P	677782-90-0P	677782-91-1P	677782-92-2P	677782-93-3P
	677782-94-4P	677782-95-5P	677782-96-6P	677782-97-7P	677782-98-8P
	677782-99-9P	677783-00-5P	677783-01-6P	677783-02-7P	677783-03-8P
	677783-04-9P	677783-05-0P	677783-06-1P	677783-07-2P	677783-08-3P
	677783-09-4P	677783-10-7P	677783-11-8P	677783-12-9P	677783-13-0P
	677783-14-1P	677783-15-2P	677783-16-3P	677783-17-4P	677783-18-5P
	677783-19-6P	677783-20-9P	677783-21-0P	677783-22-1P	677783-23-2P
	677783-24-3P	677783-25-4P	677783-26-5P	677783-27-6P	677783-28-7P
	677783-29-8P	677783-30-1P	677783-31-2P	677783-32-3P	677783-33-4P
	677783-34-5P	677783-35-6P	677783-36-7P	677783-37-8P	677783-38-9P
	677783-39-0P	677783-40-3P	677783-41-4P	677783-42-5P	677783-43-6P
	677783-44-7P	677783-45-8P	677783-46-9P	677783-47-0P	677783-48-1P
	677783-49-2P	677783-50-5P	677783-51-6P	677783-52-7P	677783-53-8P
	677783-54-9P	677783-55-0P	677783-56-1P	677783-57-2P	677783-58-3P
	677783-59-4P	677783-60-7P	677783-61-8P	677783-62-9P	677783-63-0P
	677783-64-1P	677783-65-2P	677783-66-3P	677783-67-4P	677783-68-5P
	677783-69-6P	677783-70-9P	677783-71-0P	677783-72-1P	677783-73-2P
	677783-74-3P	677783-75-4P	677783-76-5P	677783-77-6P	677783-78-7P
	677783-79-8P	677783-80-1P	677783-81-2P	677783-82-3P	677783-83-4P
	677783-84-5P	677783-85-6P	677783-86-7P	677783-87-8P	677783-88-9P
	677783-89-0P	677783-90-3P	677783-91-4P	677783-92-5P	677783-93-6P
	677783-94-7P	677783-95-8P	677783-96-9P	677783-97-0P	677783-98-1P
	677783-99-2P	677784-00-8P	677784-01-9P	677784-02-0P	677784-03-1P
	677784-04-2P	677784-05-3P	677784-06-4P	677784-07-5P	677784-08-6P
	677784-09-7P	677784-10-0P	677784-11-1P	677784-12-2P	677784-13-3P
	677784-14-4P	677784-15-5P	677784-16-6P	677784-17-7P	677784-18-8P
	677784-19-9P	677784-20-2P	677784-21-3P	677784-22-4P	677784-23-5P
	677784-24-6P	677784-25-7P	677784-26-8P	677784-27-9P	677784-28-0P
	677784-29-1P	677784-30-4P	677784-31-5P	677784-32-6P	677784-33-7P
	677784-34-8P	677784-35-9P	677784-36-0P	677784-37-1P	677784-38-2P
	677784-39-3P	677784-40-6P	677784-41-7P	677784-42-8P	677784-43-9P
	677784-44-0P	677784-45-1P	677784-46-2P	677784-47-3P	677784-48-4P
	677784-49-5P	677784-50-8P	677784-51-9P	677784-52-0P	677784-53-1P
	677784-54-2P	677784-55-3P	677784-56-4P	677784-57-5P	677784-58-6P
	677784-59-7P	677784-60-0P	677784-61-1P	677784-62-2P	677784-63-3P
	677784-64-4P	677784-65-5P	677784-66-6P	677784-67-7P	677784-68-8P
	677784-69-9P	677784-70-2P	677784-71-3P	677784-72-4P	677784-73-5P
	677784-74-6P	677784-75-7P	677784-76-8P	677784-77-9P	677784-78-0P
	677784-79-1P	677784-80-4P	677784-81-5P	677784-82-6P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT	677784-83-7P	677784-84-8P	677784-85-9P	677784-86-0P	677784-87-1P
	677784-88-2P	677784-89-3P	677784-90-6P	677784-91-7P	677784-92-8P
	677784-93-9P	677784-94-0P	677784-95-1P	677784-96-2P	677784-97-3P
	677784-98-4P	677784-99-5P	677785-00-1P	677785-01-2P	677785-02-3P
	677785-03-4P	677785-04-5P	677785-05-6P	677785-06-7P	677785-07-8P
	677785-08-9P	677785-09-0P	677785-10-3P	677785-11-4P	677785-12-5P
	677785-13-6P	677785-14-7P	677785-15-8P	677785-16-9P	677785-17-0P
	677785-18-1P	677785-19-2P	677785-20-5P	677785-21-6P	677785-22-7P
	677785-23-8P	677785-24-9P	677785-25-0P	677785-26-1P	677785-27-2P
	677785-28-3P	677785-29-4P	677785-30-7P	677785-31-8P	677785-32-9P
	677785-33-0P	677785-34-1P	677785-35-2P	677785-36-3P	677785-37-4P

677785-38-5P	677785-39-6P	677785-40-9P	677785-41-0P	677785-42-1P
677785-43-2P	677785-44-3P	677785-45-4P	677785-46-5P	677785-47-6P
677785-48-7P	677785-49-8P	677785-50-1P	677785-51-2P	677785-52-3P
677785-53-4P	677785-54-5P	677785-56-7P	677785-58-9P	677785-60-3P
677785-62-5P	677785-64-7P	677785-66-9P	677785-68-1P	677785-70-5P
677785-72-7P	677785-74-9P	677785-76-1P	677785-78-3P	677785-80-7P
677785-82-9P	677785-83-0P	677785-84-1P	677785-85-2P	677785-86-3P
677785-87-4P	677785-88-5P	677785-89-6P	677785-90-9P	677785-92-1P
677785-94-3P	677785-96-5P	677785-97-6P	677785-99-8P	677786-00-4P
677786-01-5P	677786-02-6P	677786-03-7P	677786-04-8P	677786-05-9P
677786-06-0P	677786-07-1P	677786-08-2P	677786-09-3P	677786-10-6P
677786-11-7P	677786-12-8P	677786-13-9P	677786-14-0P	677786-15-1P
677786-16-2P	677786-17-3P	677786-18-4P	677786-19-5P	677786-20-8P
677786-21-9P	677786-22-0P	677786-23-1P	677786-24-2P	677786-25-3P
677786-26-4P	677786-27-5P	677786-28-6P	677786-29-7P	677786-30-0P
677786-31-1P	677786-32-2P	677786-33-3P	677786-34-4P	677786-35-5P
677786-36-6P	677786-37-7P	677786-38-8P	677786-39-9P	677786-40-2P
677786-41-3P	677786-42-4P	677786-43-5P	677786-44-6P	677786-45-7P
677786-46-8P	677786-47-9P	677786-48-0P	677786-49-1P	677786-50-4P
677786-51-5P	677786-52-6P	677786-53-7P	677786-54-8P	677786-55-9P
677786-56-0P	677786-57-1P	677786-58-2P	677786-59-3P	677786-60-6P
677786-61-7P	677786-62-8P	677786-63-9P	677786-64-0P	677786-65-1P
677786-66-2P	677786-67-3P	677786-68-4P	677786-69-5P	677786-70-8P
677786-71-9P	677786-72-0P	677786-73-1P	677786-74-2P	677786-75-3P
677786-76-4P	677786-77-5P	677786-78-6P	677786-79-7P	677786-80-0P
677786-81-1P	677786-82-2P	677786-83-3P	677786-84-4P	677786-85-5P
677786-86-6P	677786-87-7P	677786-88-8P	677786-89-9P	677786-90-2P
677786-91-3P	677786-92-4P	677786-93-5P	677786-94-6P	677786-95-7P
677786-96-8P	677786-97-9P	677786-98-0P	677786-99-1P	677787-00-7P
677787-01-8P	677787-02-9P	677787-03-0P	677787-04-1P	677787-05-2P
677787-06-3P	677787-07-4P	677787-08-5P	677787-09-6P	677787-10-9P
677787-11-0P	677787-12-1P	677787-13-2P	677787-14-3P	677787-15-4P
677787-16-5P	677787-17-6P	677787-18-7P	677787-19-8P	677787-20-1P
677787-21-2P	677787-22-3P	677787-23-4P	677787-24-5P	677787-25-6P
677787-26-7P	677787-27-8P	677787-28-9P	677787-29-0P	677787-30-3P
677787-31-4P	677787-32-5P	677787-33-6P	677787-34-7P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT	677787-35-8P	677787-36-9P	677787-37-0P	677787-38-1P	677787-39-2P
	677787-40-5P	677787-41-6P	677787-42-7P	677787-43-8P	677787-44-9P
	677787-45-0P	677787-46-1P	677787-47-2P	677787-48-3P	677787-49-4P
	677787-50-7P	677787-51-8P	677787-52-9P	677787-53-0P	677787-54-1P
	677787-56-3P	677787-58-5P	677787-60-9P	677787-62-1P	677787-64-3P
	677787-65-4P	677787-66-5P	677787-67-6P	677787-68-7P	677787-69-8P
	677787-70-1P	677787-71-2P	677787-72-3P	677787-73-4P	677787-74-5P
	677787-75-6P	677787-76-7P	677787-77-8P	677787-78-9P	677787-79-0P
	677787-80-3P	677787-81-4P	677787-82-5P	677787-83-6P	677787-84-7P
	677787-85-8P	677787-86-9P	677787-87-0P	677787-88-1P	677787-89-2P
	677787-90-5P	677787-91-6P	677787-92-7P	677787-93-8P	677787-94-9P
	677787-95-0P	677787-96-1P	677787-97-2P	677787-98-3P	677787-99-4P
	677788-00-0P	677788-01-1P	677788-02-2P	677788-03-3P	677788-04-4P
	677788-05-5P	677788-06-6P	677788-07-7P	677788-08-8P	677788-09-9P
	677788-10-2P	677788-11-3P	677788-12-4P	677788-13-5P	677788-14-6P
	677788-15-7P	677788-16-8P	677788-17-9P	677788-18-0P	677788-19-1P
	677788-20-4P	677788-21-5P	677788-22-6P	677788-23-7P	677788-24-8P
	677788-25-9P	677788-26-0P	677788-27-1P	677788-28-2P	677788-29-3P
	677788-30-6P	677788-31-7P	677788-32-8P	677788-33-9P	677788-34-0P
	677788-35-1P	677788-36-2P	677788-37-3P	677788-38-4P	677788-39-5P
	677788-40-8P	677788-41-9P	677788-42-0P	677788-43-1P	677788-44-2P
	677788-45-3P	677788-46-4P	677788-47-5P	677788-48-6P	677788-49-7P

677788-50-0P	677788-51-1P	677788-52-2P	677788-53-3P	677788-54-4P
677788-55-5P	677788-56-6P	677788-57-7P	677788-58-8P	677788-59-9P
677788-60-2P	677788-61-3P	677788-62-4P	677788-63-5P	677788-64-6P
677788-65-7P	677788-66-8P	677788-67-9P	677788-68-0P	677788-69-1P
677788-70-4P	677788-71-5P	677788-72-6P	677788-73-7P	677788-74-8P
677788-75-9P	677788-76-0P	677788-77-1P	677788-78-2P	677788-79-3P
677788-80-6P	677788-81-7P	677788-82-8P	677788-83-9P	677788-84-0P
677788-85-1P	677788-86-2P	677788-87-3P	677788-88-4P	677788-89-5P
677788-90-8P	677788-91-9P	677788-92-0P	677788-93-1P	677788-94-2P
677788-95-3P	677788-96-4P	677788-97-5P	677788-98-6P	677788-99-7P
677789-00-3P	677789-01-4P	677789-02-5P	677789-03-6P	677789-04-7P
677789-05-8P	677789-06-9P	677789-07-0P	677789-08-1P	677789-09-2P
677789-10-5P	677789-11-6P	677789-12-7P	677789-13-8P	677789-15-0P
677789-16-1P	677789-17-2P	677789-18-3P	677789-19-4P	677789-20-7P
677789-21-8P	677789-22-9P	677789-23-0P	677789-24-1P	677789-25-2P
677789-26-3P	677789-27-4P	677789-28-5P	677789-29-6P	677789-30-9P
677789-31-0P	677789-32-1P	677789-33-2P	677789-34-3P	677789-35-4P
677789-36-5P	677789-37-6P	677789-38-7P	677789-39-8P	677789-40-1P
677789-41-2P	677789-42-3P	677789-43-4P	677789-44-5P	677789-45-6P
677789-46-7P	677789-47-8P	677789-48-9P	677789-49-0P	677789-50-3P
677789-51-4P	677789-52-5P	677789-53-6P	677789-54-7P	677789-55-8P
677789-56-9P	677789-57-0P	677789-58-1P	677789-59-2P	677789-60-5P
677789-61-6P	677789-62-7P	677789-63-8P	677789-64-9P	677789-65-0P
677789-66-1P	677789-67-2P	677789-68-3P	677789-69-4P	677789-70-7P
677789-71-8P	677789-72-9P	677789-73-0P	677789-74-1P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

677789-75-2P	677789-76-3P	677789-77-4P	677789-78-5P	677789-79-6P
677789-80-9P	677789-81-0P	677789-82-1P	677789-83-2P	677789-84-3P
677789-85-4P	677789-86-5P	677789-87-6P	677789-88-7P	677789-89-8P
677789-90-1P	677789-91-2P	677789-92-3P	677789-93-4P	677789-94-5P
677789-95-6P	677789-96-7P	677789-97-8P	677789-98-9P	677789-99-0P
677790-00-0P	677790-01-1P	677790-02-2P	677790-03-3P	677790-04-4P
677790-05-5P	677790-06-6P	677790-07-7P	677790-08-8P	677790-09-9P
677790-10-2P	677790-11-3P	677790-12-4P	677790-13-5P	677790-14-6P
677790-15-7P	677790-16-8P	677790-17-9P	677790-18-0P	677790-19-1P
677790-20-4P	677790-21-5P	677790-22-6P	677790-23-7P	677790-24-8P
677790-25-9P	677790-26-0P	677790-27-1P	677790-28-2P	677790-29-3P
677790-30-6P	677790-31-7P	677790-32-8P	677790-33-9P	677790-34-0P
677790-35-1P	677790-36-2P	677790-37-3P	677790-38-4P	677790-39-5P
677790-40-8P	677790-41-9P	677790-42-0P	677790-43-1P	677790-44-2P
677790-45-3P	677790-46-4P	677790-47-5P	677790-48-6P	677790-49-7P
677790-50-0P	677790-51-1P	677790-52-2P	677790-53-3P	677790-54-4P
677790-55-5P	677790-56-6P	677790-57-7P	677790-58-8P	677790-59-9P
677790-60-2P	677790-61-3P	677790-62-4P	677790-63-5P	677790-64-6P
677790-65-7P	677790-66-8P	677790-67-9P	677790-68-0P	677790-69-1P
677790-70-4P	677790-71-5P	677790-72-6P	677790-73-7P	677790-74-8P
677790-75-9P	677790-76-0P	677790-77-1P	677790-78-2P	677790-79-3P
677790-80-6P	677790-81-7P	677790-82-8P	677790-83-9P	677790-84-0P
677790-85-1P	677790-86-2P	677790-87-3P	677790-88-4P	677790-89-5P
677790-90-8P	677790-91-9P	677790-92-0P	677790-93-1P	677790-94-2P
677790-95-3P	677790-96-4P	677790-97-5P	677790-98-6P	677790-99-7P
677791-00-3P	677791-01-4P	677791-02-5P	677791-03-6P	677791-04-7P
677791-05-8P	677791-06-9P	677791-07-0P	677791-08-1P	677791-09-2P
677791-10-5P	677791-11-6P	677791-12-7P	677791-13-8P	677791-14-9P
677791-15-0P	677791-16-1P	677791-17-2P	677791-18-3P	677791-19-4P
677791-20-7P	677791-21-8P	677791-22-9P	677791-23-0P	677791-24-1P
677791-25-2P	677791-26-3P	677791-27-4P	677791-28-5P	677791-29-6P
677791-30-9P	677791-31-0P	677791-32-1P	677791-33-2P	677791-34-3P
677791-35-4P	677791-36-5P	677791-37-6P	677791-38-7P	677791-39-8P

677791-40-1P	677791-41-2P	677791-42-3P	677791-43-4P	677791-44-5P
677791-45-6P	677791-46-7P	677791-47-8P	677791-48-9P	677791-49-0P
677791-50-3P	677791-51-4P	677791-52-5P	677791-53-6P	677791-54-7P
677791-55-8P	677791-56-9P	677791-57-0P	677791-58-1P	677791-59-2P
677791-60-5P	677791-61-6P	677791-62-7P	677791-63-8P	677791-64-9P
677791-65-0P	677791-66-1P	677791-67-2P	677791-68-3P	677791-69-4P
677791-70-7P	677791-71-8P	677791-72-9P	677791-73-0P	677791-74-1P
677791-75-2P	677791-76-3P	677791-77-4P	677791-78-5P	677791-79-6P
677791-80-9P	677791-81-0P	677791-82-1P	677791-83-2P	677791-84-3P
677791-85-4P	677791-86-5P	677791-87-6P	677791-88-7P	677791-89-8P
677791-90-1P	677791-91-2P	677791-92-3P	677791-93-4P	677791-94-5P
677791-95-6P	677791-96-7P	677791-97-8P	677791-98-9P	677791-99-0P
677792-00-6P	677792-01-7P	677792-02-8P	677792-03-9P	677792-04-0P
677792-05-1P	677792-06-2P	677792-07-3P	677792-08-4P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT	677792-09-5P	677792-10-8P	677792-11-9P	677792-12-0P	677792-13-1P
	677792-14-2P	677792-15-3P	677792-16-4P	677792-17-5P	677792-18-6P
	677792-19-7P	677792-20-0P	677792-21-1P	677792-22-2P	677792-23-3P
	677792-24-4P	677792-26-6P	677792-27-7P	677792-28-8P	677792-29-9P
	677792-30-2P	677792-31-3P	677792-32-4P	677792-33-5P	677792-34-6P
	677792-35-7P	677792-36-8P	677792-37-9P	677792-38-0P	677792-39-1P
	677792-40-4P	677792-41-5P	677792-42-6P	677792-43-7P	677792-44-8P
	677792-45-9P	677792-46-0P	677792-47-1P	677792-48-2P	677792-49-3P
	677792-50-6P	677792-51-7P	677792-52-8P	677792-53-9P	677792-54-0P
	677792-55-1P	677792-56-2P	677792-57-3P	677792-58-4P	677792-59-5P
	677792-60-8P	677792-61-9P	677792-62-0P	677792-63-1P	677792-64-2P
	677792-65-3P	677792-66-4P	677792-67-5P	677792-68-6P	677792-69-7P
	677792-70-0P	677792-71-1P	677792-72-2P	677792-73-3P	677792-74-4P
	677792-75-5P	677792-76-6P	677792-77-7P	677792-78-8P	677792-79-9P
	677792-80-2P	677792-81-3P	677792-82-4P	677792-83-5P	677792-84-6P
	677792-85-7P	677792-86-8P	677792-87-9P	677792-88-0P	677792-89-1P
	677792-90-4P	677792-91-5P	677792-92-6P	677792-93-7P	677792-94-8P
	677792-95-9P	677792-96-0P	677792-97-1P	677792-98-2P	677792-99-3P
	677793-00-9P	677793-01-0P	677793-02-1P	677793-03-2P	677793-04-3P
	677793-05-4P	677793-06-5P	677793-07-6P	677793-08-7P	677793-09-8P
	677793-10-1P	677793-11-2P	677793-12-3P	677793-13-4P	677793-14-5P
	677793-15-6P	677793-16-7P	677793-17-8P	677793-18-9P	677793-19-0P
	677793-20-3P	677793-21-4P	677793-22-5P	677793-23-6P	677793-24-7P
	677793-25-8P	677793-26-9P	677793-27-0P	677793-28-1P	677793-29-2P
	677793-30-5P	677793-31-6P	677793-32-7P	677793-33-8P	677793-34-9P
	677793-35-0P	677793-36-1P	677793-37-2P	677793-38-3P	677793-39-4P
	677793-40-7P	677793-41-8P	677793-42-9P	677793-43-0P	677793-44-1P
	677793-45-2P	677793-46-3P	677793-47-4P	677793-48-5P	677793-49-6P
	677793-50-9P	677793-51-0P	677793-52-1P	677793-53-2P	677793-54-3P
	677793-55-4P	677793-56-5P	677793-57-6P	677793-58-7P	677793-59-8P
	677793-60-1P	677793-61-2P	677793-62-3P	677793-63-4P	677793-64-5P
	677793-65-6P	677793-66-7P	677793-67-8P	677793-68-9P	677793-69-0P
	677793-70-3P	677793-71-4P	677793-72-5P	677793-73-6P	677793-74-7P
	677793-75-8P	677793-76-9P	677793-77-0P	677793-78-1P	677793-79-2P
	677793-80-5P	677793-81-6P	677793-82-7P	677793-83-8P	677793-84-9P
	677793-85-0P	677793-86-1P	677793-87-2P	677793-88-3P	677793-89-4P
	677793-90-7P	677793-91-8P	677793-92-9P	677793-93-0P	677793-94-1P
	677793-95-2P	677793-96-3P	677793-97-4P	677793-98-5P	677793-99-6P
	677794-00-2P	677794-01-3P	677794-02-4P	677794-03-5P	677794-04-6P
	677794-05-7P	677794-06-8P	677794-07-9P	677794-08-0P	677794-09-1P
	677794-10-4P	677794-11-5P	677794-12-6P	677794-13-7P	677794-14-8P
	677794-15-9P	677794-16-0P	677794-17-1P	677794-18-2P	677794-19-3P
	677794-20-6P	677794-21-7P	677794-22-8P	677794-23-9P	677794-24-0P
	677794-25-1P	677794-26-2P	677794-27-3P	677794-28-4P	677794-29-5P

677794-30-8P	677794-31-9P	677794-32-0P	677794-33-1P	677794-34-2P
677794-35-3P	677794-36-4P	677794-37-5P	677794-38-6P	677794-39-7P
677794-40-0P	677794-41-1P	677794-42-2P	677794-43-3P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT	677794-44-4P	677794-45-5P	677794-46-6P	677794-47-7P	677794-48-8P
	677794-49-9P	677794-50-2P	677794-51-3P	677794-52-4P	677794-53-5P
	677794-54-6P	677794-55-7P	677794-56-8P	677794-57-9P	677794-58-0P
	677794-59-1P	677794-60-4P	677794-61-5P	677794-62-6P	677794-63-7P
	677794-64-8P	677794-65-9P	677794-66-0P	677794-67-1P	677794-68-2P
	677794-69-3P	677794-70-6P	677794-71-7P	677794-72-8P	677794-73-9P
	677794-74-0P	677794-75-1P	677794-76-2P	677794-77-3P	677794-78-4P
	677794-79-5P	677794-80-8P	677794-81-9P	677794-82-0P	677794-83-1P
	677794-84-2P	677794-85-3P	677794-86-4P	677794-87-5P	677794-88-6P
	677794-89-7P	677794-90-0P	677794-91-1P	677794-92-2P	677794-93-3P
	677794-94-4P	677794-95-5P	677794-96-6P	677794-97-7P	677794-98-8P
	677794-99-9P	677795-00-5P	677795-01-6P	677795-02-7P	677795-03-8P
	677795-04-9P	677795-05-0P	677795-06-1P	677795-07-2P	677795-08-3P
	677795-09-4P	677795-10-7P	677795-11-8P	677795-12-9P	677795-13-0P
	677795-14-1P	677795-15-2P	677795-16-3P	677795-17-4P	677795-18-5P
	677795-19-6P	677795-20-9P	677795-21-0P	677795-22-1P	677795-23-2P
	677795-24-3P	677795-25-4P	677795-26-5P	677795-27-6P	677795-28-7P
	677795-29-8P	677795-30-1P	677795-31-2P	677795-32-3P	677795-33-4P
	677795-34-5P	677795-35-6P	677795-36-7P	677795-37-8P	677795-38-9P
	677795-39-0P	677795-40-3P	677795-41-4P	677795-42-5P	677795-43-6P
	677795-44-7P	677795-45-8P	677795-46-9P	677795-47-0P	677795-48-1P
	677795-49-2P	677795-50-5P	677795-51-6P	677795-52-7P	677795-53-8P
	677795-54-9P	677795-55-0P	677795-56-1P	677795-57-2P	677795-58-3P
	677795-59-4P	677795-60-7P	677795-61-8P	677795-62-9P	677795-63-0P
	677795-64-1P	677795-65-2P	677795-66-3P	677795-67-4P	677795-68-5P
	677795-69-6P	677795-70-9P	677795-71-0P	677795-72-1P	677795-73-2P
	677795-74-3P	677795-75-4P	677795-76-5P	677795-77-6P	677795-78-7P
	677795-79-8P	677795-80-1P	677795-81-2P	677795-82-3P	677795-83-4P
	677795-84-5P	677795-85-6P	677795-86-7P	677795-87-8P	677795-88-9P
	677795-89-0P	677795-90-3P	677795-91-4P	677795-92-5P	677795-93-6P
	677795-94-7P	677795-95-8P	677795-96-9P	677795-97-0P	677795-98-1P
	677795-99-2P	677796-00-8P	677796-01-9P	677796-02-0P	677796-03-1P
	677796-04-2P	677796-05-3P	677796-06-4P	677796-07-5P	677796-08-6P
	677796-09-7P	677796-10-0P	677796-11-1P	677796-12-2P	677796-13-3P
	677796-14-4P	677796-15-5P	677796-16-6P	677796-17-7P	677796-18-8P
	677796-19-9P	677796-20-2P	677796-21-3P	677796-22-4P	677796-23-5P
	677796-24-6P	677796-25-7P	677796-26-8P	677796-27-9P	677796-28-0P
	677796-29-1P	677796-30-4P	677796-31-5P	677796-32-6P	677796-33-7P
	677796-34-8P	677796-35-9P	677796-36-0P	677796-37-1P	677796-38-2P
	677796-39-3P	677796-40-6P	677796-41-7P	677796-42-8P	677796-43-9P
	677796-44-0P	677796-45-1P	677796-46-2P	677796-47-3P	677796-48-4P
	779353-01-4P	779353-02-5P	779353-03-6P	779353-04-7P	779353-05-8P
	779353-06-9P	779353-07-0P	779353-08-1P	779353-09-2P	779353-10-5P
	779353-11-6P	779353-12-7P	779353-13-8P	779353-14-9P	779353-15-0P
	779353-16-1P	779353-17-2P	779353-18-3P	779353-19-4P	779353-20-7P
	779353-21-8P	779353-22-9P	779353-23-0P	779353-24-1P	779353-25-2P
	779353-26-3P	779353-27-4P	779353-28-5P	779353-29-6P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT	779353-30-9P	779353-31-0P	779353-32-1P	779353-33-2P	779353-34-3P
	779353-35-4P	779353-36-5P	779353-37-6P	779353-38-7P	779353-39-8P
	779353-40-1P	779353-41-2P	779353-42-3P	779353-43-4P	779353-44-5P
	779353-45-6P	779353-46-7P	779353-47-8P	779353-48-9P	779353-49-0P

779353-50-3P 779353-51-4P 779353-52-5P 779353-53-6P 779353-54-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT 220904-92-7P 267413-25-2P, 1H-Indazole-5-methanamine 267874-51-1P
672325-34-7P 672325-35-8P 673475-70-2P 779353-77-4P 1008793-88-1P

RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT 56-91-7 59-48-3 75-31-0, 2-Propanamine, reactions 75-64-9, reactions
89-75-8 94-02-0 98-80-6 98-88-4, Benzoyl chloride 100-46-9,
Benzenemethanamine, reactions 100-58-3 100-60-7 102-49-8 105-53-3
108-00-9 108-59-8 108-91-8, Cyclohexanamine, reactions 109-01-3
109-04-6 109-74-0, Butanenitrile 109-85-3 109-96-6 110-85-0,
Piperazine, reactions 110-89-4, Piperidine, reactions 110-91-8,
Morpholine, reactions 110-97-4 111-42-2, reactions 123-75-1,
Pyrrolidine, reactions 123-90-0, Thiomorpholine 124-68-5 138-39-6
139-02-6 141-43-5, reactions 141-78-6, Acetic acid ethyl ester,
reactions 156-87-6 288-32-4, 1H-Imidazole, reactions 352-13-6
494-52-0 617-89-0, 2-Furanmethanamine 622-40-2, 4-Morpholineethanol
677-22-5 765-30-0, Cyclopropanamine 822-55-9, 1H-Imidazole-5-methanol
930-45-0 930-69-8 931-15-7 931-16-8 931-50-0 934-28-1
1003-03-8, Cyclopentanamine 1003-09-4 1068-55-9 1099-45-2
1194-02-1 1436-60-8 1436-61-9 1449-46-3 1484-84-0,
2-Piperidineethanol 1710-98-1 1820-80-0, 1H-Pyrazol-3-amine
1989-53-3 2026-48-4 2133-40-6 2251-65-2 2450-71-7,
2-Propyn-1-amine 2516-34-9, Cyclobutanamine 2516-47-4,
Cyclopropanemethanamine 2577-48-2 2706-56-1, 2-Pyridineethanamine
2719-27-9, Cyclohexanecarbonyl chloride 2749-11-3 2786-07-4
2842-38-8 2905-60-4 2955-88-6, 1-Pyrrolidineethanol 3034-53-5
3082-64-2 3222-48-8 3433-37-2, 2-Piperidinemethanol 3535-37-3
3731-51-9, 2-Pyridinemethanamine 3731-52-0, 3-Pyridinemethanamine
3731-53-1, 4-Pyridinemethanamine 3789-59-1 4244-84-2 4276-09-9
4301-14-8 4393-16-2 4543-47-9, 3-Furanmethanamine 4795-29-3
5004-07-9 5271-67-0, 2-Thiophenecarbonyl chloride 5292-21-7,
Cyclohexanecarboxylic acid 5587-42-8 5625-67-2, 2-Piperazinone 5680-79-5
5691-15-6 5691-21-4 5908-62-3 5993-91-9 6168-72-5 6232-11-7
6271-78-9 6335-76-8 6575-24-2 6859-99-0, 3-Piperidinol 6921-34-2
6937-16-2 7154-66-7 7175-81-7 7486-35-3 7531-52-4 7583-53-1
10070-92-5, 5-Pyrimidinecarboxaldehyde 10314-98-4 10316-79-7
10472-24-9 13325-10-5 14273-46-2 16466-97-0 16617-46-2
17201-43-3 17413-10-4 17850-11-2 19847-10-0, 2-Pyrazinecarbonyl
chloride 20781-20-8 20980-22-7 21615-34-9 22526-47-2 22724-81-8
23356-96-9 23719-80-4 24717-01-9 25054-53-9,
1,3-Benzodioxole-5-carbonyl chloride 27489-62-9 28188-41-2
28250-37-5 28697-07-6 29364-29-2 29602-39-9 29840-56-0
30318-99-1 33797-51-2 35320-23-1 36489-03-9 39021-62-0
39546-32-2, 4-Piperidinecarboxamide 40172-95-0 40482-12-0
50901-42-3, 4-Pyridazinecarboxaldehyde 51387-90-7 55551-49-0
55745-74-9 55686-13-1 57260-73-8 59260-76-3 60419-23-0
64099-82-7 65873-72-5 66228-31-7 66401-62-5 67319-76-0,
1H-Imidazole-1-butanamine 68076-36-8 68832-13-3 69385-30-4
70258-19-4 70449-23-9 71581-92-5 72235-53-1 73874-95-0
74111-21-0 75178-96-0 78190-11-1 79286-74-1 80696-30-6
81881-74-5, 1H-Indole-5-methanamine 84025-81-0 84951-44-0 85459-20-7
87120-72-7 88675-25-6 89363-94-0 89364-31-8 90905-31-0
90905-32-1 97004-04-1 98593-51-2 101252-53-3 102619-05-6
106940-10-7 108467-99-8 108468-00-4 114715-38-7 114715-39-8
115576-91-5 117720-58-8 120538-52-5 120747-84-4 121492-06-6
122536-76-9 126747-14-6 131379-40-3 132664-85-8 133181-64-3
135132-34-2 137583-05-2 142643-29-6 144222-22-0 144222-23-1

147081-44-5	147081-49-0	150349-36-3	155742-57-7	162167-97-7
164648-60-6,	1H-Benzimidazole-6-methanamine	165528-81-4	173282-69-4	
175205-49-9	177906-48-8	181657-56-7	181657-57-8	184637-48-7
188554-13-4	188755-01-3	195044-13-4	196929-78-9	197893-32-6
205318-52-1	213993-30-7	215305-98-9	216394-06-8	216394-07-9
216659-02-8	220298-96-4	228422-38-6	239482-98-5	250161-45-6
260794-33-0	282727-21-3			

RL: RCT (Reactant); RACT (Reactant or reagent)

IT (preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

288309-53-5	304873-65-2	306934-88-3	308795-91-7	308796-24-9
312693-18-8	321309-35-7	321330-19-2,		
2,1,3-Benzoxadiazole-5-methanamine		342029-20-3	343338-26-1	
343338-28-3	370069-31-1	387350-39-2	540787-92-6	550369-61-4
672307-83-4	672325-00-7	672325-01-8	672325-02-9	672325-03-0
672325-04-1	672325-05-2	672325-06-3	672325-07-4	672325-08-5
672325-09-6	672325-10-9	672325-11-0	672325-12-1	672325-13-2
672325-14-3	672325-15-4	672325-16-5	672325-18-7	672325-19-8
672325-20-1	672325-21-2	672325-22-3	672325-23-4	672325-24-5
672325-25-6	672325-26-7	672325-27-8	672325-28-9	672325-29-0
672325-30-3	672325-31-4	672325-32-5	672325-33-6	672325-36-9
672325-37-0	672325-38-1	672325-39-2	672325-40-5	672325-41-6
672325-42-7	672325-43-8	672325-44-9	672325-45-0	672325-46-1
672325-47-2	672325-48-3	672325-49-4	672325-50-7	672325-51-8
672325-52-9	672325-53-0	672325-54-1	672325-55-2	672325-56-3
672325-57-4	672325-58-5	672325-59-6	672325-65-4	672325-66-5
672325-68-7	672325-70-1	672325-71-2	672325-74-5	672325-75-6
672325-76-7	672325-78-9	672325-83-6	672325-96-1	672326-19-1
672326-21-5	672326-27-1	672326-31-7	672326-35-1	672326-36-2
672326-37-3	747409-26-3	779353-74-1	779353-75-2	779353-76-3
779353-78-5	779353-82-1	954582-87-7		

RL: RCT (Reactant); RACT (Reactant or reagent)

IT (preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

4687-37-0P	7149-42-0P	10406-24-3P	10406-25-4P	13374-30-6P
13374-31-7P	13669-10-8P	14613-37-7P	15961-46-3P	15971-92-3P
25372-03-6P	29274-13-3P	32111-34-5P	33149-25-6P	41607-95-8P
41886-04-8P	42460-90-2P	43024-14-2P	43024-15-3P	50671-05-1P
56622-54-9P	57489-70-0P	57489-77-7P	60868-41-9P	61098-37-1P
62124-77-0P	62718-28-9P	64127-44-2P	65113-25-9P	68327-03-7P
68327-04-8P	68419-38-5P	72851-86-6P	81581-27-3P	92053-25-3P
101498-88-8P	102297-41-6P	103639-57-2P	110295-94-8P	111080-65-0P
111080-66-1P	114040-06-1P	114524-22-0P	120747-85-5P	120747-86-6P
125732-13-0P	134149-19-2P	135132-35-3P	167414-75-7P	172348-74-2P
183958-56-7P	189017-89-8P	189018-29-9P	189018-71-1P	203436-48-0P
213764-26-2P	220324-83-4P	221121-45-5P	294647-97-5P	304873-62-9P
324570-25-4P	342412-64-0P	394734-84-0P	618446-34-7P	672323-06-7P
672323-07-8P	672323-09-0P	672323-11-4P	672323-13-6P	672323-15-8P
672323-17-0P	672323-19-2P	672323-21-6P	672323-22-7P	672323-23-8P
672323-25-0P	672323-26-1P	672323-27-2P	672323-29-4P	672323-30-7P
672323-32-9P	672323-34-1P	672323-36-3P	672323-37-4P	672323-39-6P
672323-40-9P	672323-41-0P	672323-43-2P	672323-44-3P	672323-46-5P
672323-47-6P	672323-49-8P	672323-51-2P	672323-53-4P	672323-55-6P
672323-56-7P	672323-57-8P	672323-59-0P	672323-61-4P	672323-63-6P
672323-64-7P	672323-66-9P	672323-68-1P	672323-70-5P	672323-72-7P
672323-74-9P	672323-75-0P	672323-78-3P	672323-80-7P	672323-81-8P
672323-82-9P	672323-84-1P	672323-86-3P	672323-88-5P	672323-89-6P
672323-91-0P	672323-94-3P	672323-95-4P	672323-97-6P	672323-99-8P
672324-01-5P	672324-03-7P	672324-05-9P	672324-07-1P	672324-09-3P
672324-11-7P	672324-13-9P	672324-15-1P	672324-17-3P	672324-19-5P
672324-21-9P	672324-23-1P	672324-25-3P	672324-27-5P	672324-28-6P
672324-30-0P	672324-31-1P	672324-32-2P	672324-34-4P	672324-36-6P
672324-38-8P	672324-39-9P	672324-41-3P	672324-42-4P	672324-43-5P
672324-45-7P	672324-46-8P	672324-47-9P	672324-49-1P	672324-51-5P

672324-53-7P	672324-55-9P	672324-57-1P	672324-59-3P	672324-61-7P
672324-63-9P	672324-65-1P	672324-66-2P	672324-68-4P	672324-69-5P
672324-71-9P	672324-73-1P	672324-75-3P	672324-77-5P	672324-80-0P
672324-82-2P	672324-83-3P	672324-84-4P	672324-85-5P	672324-86-6P
672324-87-7P	672324-88-8P	672324-89-9P	672324-90-2P	672324-91-3P
672324-92-4P	672324-93-5P	672324-94-6P	672324-95-7P	672324-96-8P
672324-97-9P	672324-98-0P	672324-99-1P	672325-60-9P	672325-61-0P
672325-62-1P	672325-63-2P	672325-64-3P	672325-72-3P	672325-73-4P
672325-80-3P	672325-85-8P	672325-87-0P	672325-89-2P	672325-92-7P
672325-94-9P	672326-00-0P	672326-02-2P	672326-04-4P	672326-06-6P
672326-08-8P	672326-10-2P	672326-14-6P	672326-16-8P	672326-33-9P
673475-51-9P	779353-55-8P	779353-56-9P	779353-57-0P	779353-58-1P
779353-59-2P	779353-60-5P	779353-61-6P	779353-62-7P	779353-63-8P
779353-64-9P	779353-65-0P	779353-66-1P	779353-67-2P	779353-68-3P
779353-69-4P	779353-70-7P	779353-71-8P	779353-72-9P	779353-73-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT	52-24-4	58-05-9	1327-53-3	Arсенic oxide (As2O3)	68335-15-9
	Hematoporphyrin D	71486-22-1	82413-20-5	82640-04-8	107868-30-4
	112809-51-5	120511-73-1	125317-39-7	129453-61-8	174722-31-7
	179324-69-7	180288-69-1	192391-48-3	205923-56-4	206181-63-7
	216503-57-0	216974-75-3			

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT	677278-50-1P	677278-51-2P	677278-52-3P	677278-53-4P	677278-54-5P
	677278-55-6P	677278-56-7P	677278-57-8P	677278-58-9P	677278-59-0P
	677278-60-3P	677278-61-4P	677278-62-5P	677278-63-6P	677278-64-7P
	677278-65-8P	677278-66-9P	677278-67-0P	677278-68-1P	677278-69-2P
	677278-70-5P	677278-71-6P	677278-72-7P	677278-73-8P	677278-74-9P
	677278-75-0P	677278-76-1P	677278-77-2P	677278-78-3P	677278-79-4P
	677278-80-7P	677278-81-8P	677278-82-9P	677278-83-0P	677278-84-1P
	677278-85-2P	677278-86-3P	677278-87-4P	677278-88-5P	677278-89-6P
	677278-90-9P	677278-91-0P	677278-92-1P	677278-93-2P	677278-94-3P
	677278-95-4P	677278-96-5P	677278-97-6P	677278-98-7P	677278-99-8P
	677279-00-4P	677279-01-5P	677279-02-6P	677279-03-7P	677279-04-8P
	677279-05-9P	677279-06-0P	677279-07-1P	677279-08-2P	677279-09-3P
	677279-10-6P	677279-11-7P	677279-12-8P	677279-13-9P	677279-14-0P
	677279-15-1P	677279-16-2P	677279-17-3P	677279-18-4P	677279-19-5P
	677279-20-8P	677279-21-9P	677279-22-0P	677279-23-1P	677279-24-2P
	677279-25-3P	677279-26-4P	677279-27-5P	677279-28-6P	677279-29-7P
	677279-30-0P	677279-31-1P	677279-32-2P	677279-33-3P	677279-34-4P
	677279-35-5P	677279-36-6P	677279-37-7P	677279-38-8P	677279-39-9P
	677279-40-2P	677279-41-3P	677279-42-4P	677279-43-5P	677279-44-6P
	677279-45-7P	677279-46-8P	677279-47-9P	677279-48-0P	677279-49-1P
	677279-50-4P	677279-51-5P	677279-52-6P	677279-53-7P	677279-54-8P
	677279-55-9P	677279-56-0P	677279-57-1P	677279-58-2P	677279-59-3P
	677279-60-6P	677279-61-7P	677279-62-8P	677279-63-9P	677279-64-0P
	677279-65-1P	677279-66-2P	677279-67-3P	677279-68-4P	677279-69-5P
	677279-70-8P	677279-71-9P	677279-72-0P	677279-73-1P	677279-74-2P
	677279-75-3P	677279-76-4P	677279-77-5P	677279-78-6P	677279-79-7P
	677279-80-0P	677279-81-1P	677279-82-2P	677279-83-3P	677279-84-4P
	677279-85-5P	677279-86-6P	677279-87-7P	677279-88-8P	677279-89-9P
	677279-90-2P	677279-91-3P	677279-92-4P	677279-93-5P	677279-94-6P
	677279-95-7P	677279-96-8P	677279-97-9P	677279-98-0P	677279-99-1P
	677280-00-1P	677280-01-2P	677280-02-3P	677280-03-4P	677280-04-5P
	677280-05-6P	677280-06-7P	677280-07-8P	677280-08-9P	677280-09-0P
	677280-10-3P	677280-11-4P	677280-12-5P	677280-13-6P	677280-14-7P
	677280-15-8P	677280-16-9P	677280-17-0P	677280-18-1P	677280-19-2P
	677280-20-5P	677280-21-6P	677280-22-7P	677280-23-8P	677280-24-9P
	677280-25-0P	677280-26-1P	677280-27-2P	677280-28-3P	677280-29-4P
	677280-30-7P	677280-31-8P	677280-32-9P	677280-33-0P	677280-34-1P

677280-35-2P	677280-36-3P	677280-37-4P	677280-38-5P	677280-39-6P
677280-40-9P	677280-41-0P	677280-42-1P	677280-43-2P	677280-44-3P
677280-45-4P	677280-46-5P	677280-47-6P	677280-48-7P	677280-49-8P
677280-50-1P	677280-51-2P	677280-52-3P	677280-53-4P	677280-54-5P
677280-55-6P	677280-56-7P	677280-57-8P	677280-58-9P	677280-59-0P
677280-60-3P	677280-61-4P	677280-62-5P	677280-63-6P	677280-64-7P
677280-65-8P	677280-66-9P	677280-67-0P	677280-68-1P	677280-69-2P
677280-70-5P	677280-71-6P	677280-72-7P	677280-73-8P	677280-74-9P
677280-75-0P	677280-76-1P	677280-77-2P	677280-78-3P	677280-79-4P
677280-80-7P	677280-81-8P	677280-82-9P	677280-83-0P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors for treating cancer)

IT	677280-84-1P	677280-85-2P	677280-86-3P	677280-87-4P	677280-88-5P
	677280-89-6P	677280-90-9P	677280-91-0P	677280-92-1P	677280-93-2P
	677280-94-3P	677280-95-4P	677280-96-5P	677280-97-6P	677280-98-7P
	677280-99-8P	677281-00-4P	677281-01-5P	677281-02-6P	677281-04-8P
	677281-05-9P	677281-06-0P	677281-07-1P	677281-08-2P	677281-09-3P
	677281-10-6P	677281-11-7P	677281-12-8P	677281-13-9P	677281-14-0P
	677281-15-1P	677281-16-2P	677281-17-3P	677281-18-4P	677281-19-5P
	677281-20-8P	677281-21-9P	677281-22-0P	677281-23-1P	677281-24-2P
	677281-25-3P	677281-26-4P	677281-27-5P	677281-28-6P	677281-29-7P
	677281-30-0P	677281-31-1P	677281-32-2P	677281-33-3P	677281-34-4P
	677281-35-5P	677281-36-6P	677281-37-7P	677281-38-8P	677281-39-9P
	677281-40-2P	677281-41-3P	677281-42-4P	677281-43-5P	677281-44-6P
	677281-45-7P	677281-46-8P	677281-47-9P	677281-48-0P	677281-49-1P
	677281-50-4P	677281-51-5P	677281-52-6P	677281-53-7P	677281-54-8P
	677281-55-9P	677281-56-0P	677281-57-1P	677281-58-2P	677281-59-3P
	677281-60-6P	677281-61-7P	677281-62-8P	677281-63-9P	677281-64-0P
	677281-65-1P	677281-66-2P	677281-67-3P	677281-68-4P	677281-69-5P
	677281-70-8P	677281-71-9P	677281-72-0P	677281-73-1P	677281-74-2P
	677281-75-3P	677281-76-4P	677281-77-5P	677281-78-6P	677281-79-7P
	677281-80-0P	677281-81-1P	677281-82-2P	677281-83-3P	677281-84-4P
	677281-85-5P	677281-86-6P	677281-87-7P	677281-88-8P	677281-89-9P
	677281-90-2P	677281-91-3P	677281-92-4P	677281-93-5P	677281-94-6P
	677281-95-7P	677281-96-8P	677281-97-9P	677281-98-0P	677281-99-1P
	677282-00-7P	677282-01-8P	677282-02-9P	677282-03-0P	677282-04-1P
	677282-05-2P	677282-06-3P	677282-07-4P	677282-08-5P	677282-09-6P
	677282-10-9P	677282-11-0P	677282-12-1P	677282-13-2P	677282-14-3P
	677282-15-4P	677282-16-5P	677282-17-6P	677282-18-7P	677282-19-8P
	677282-20-1P	677282-21-2P	677282-22-3P	677282-23-4P	677282-24-5P
	677282-25-6P	677282-26-7P	677282-27-8P	677282-28-9P	677282-29-0P
	677282-30-3P	677282-31-4P	677282-32-5P	677282-33-6P	677282-34-7P
	677282-35-8P	677282-36-9P	677282-37-0P	677282-38-1P	677282-39-2P
	677282-40-5P	677282-41-6P	677282-42-7P	677282-43-8P	677282-44-9P
	677282-45-0P	677282-46-1P	677282-47-2P	677282-48-3P	677282-49-4P
	677282-50-7P	677282-51-8P	677282-52-9P	677282-53-0P	677282-54-1P
	677282-55-2P	677282-56-3P	677282-57-4P	677282-58-5P	677282-59-6P
	677282-60-9P	677282-61-0P	677282-62-1P	677282-63-2P	677282-64-3P
	677282-65-4P	677282-66-5P	677282-67-6P	677282-68-7P	677282-69-8P
	677282-70-1P	677282-71-2P	677282-72-3P	677282-73-4P	677282-74-5P
	677282-75-6P	677282-76-7P	677282-77-8P	677282-78-9P	677282-79-0P
	677282-80-3P	677282-81-4P	677282-82-5P	677282-83-6P	677282-84-7P
	677282-85-8P	677282-86-9P	677282-87-0P	677282-88-1P	677282-89-2P
	677282-90-5P	677282-91-6P	677282-92-7P	677282-93-8P	677282-94-9P
	677282-95-0P	677282-96-1P	677282-97-2P	677282-98-3P	677282-99-4P
	677283-00-0P	677283-01-1P	677283-02-2P	677283-03-3P	677283-04-4P
	677283-05-5P	677283-06-6P	677283-07-7P	677283-08-8P	677283-09-9P
	677283-10-2P	677283-11-3P	677283-12-4P	677283-13-5P	677283-14-6P
	677283-15-7P	677283-16-8P	677283-17-9P	677283-18-0P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
for treating cancer)

IT	677283-19-1P	677283-20-4P	677283-21-5P	677283-22-6P	677283-23-7P
	677283-24-8P	677283-25-9P	677283-26-0P	677283-27-1P	677283-28-2P
	677283-29-3P	677283-30-6P	677283-31-7P	677283-32-8P	677283-33-9P
	677283-34-0P	677283-35-1P	677283-36-2P	677283-37-3P	677283-38-4P
	677283-39-5P	677283-40-8P	677283-41-9P	677283-42-0P	677283-43-1P
	677283-44-2P	677283-45-3P	677283-46-4P	677283-47-5P	677283-48-6P
	677283-49-7P	677283-50-0P	677283-51-1P	677283-52-2P	677283-53-3P
	677283-54-4P	677283-55-5P	677283-56-6P	677283-57-7P	677283-58-8P
	677283-59-9P	677283-60-2P	677283-61-3P	677283-62-4P	677283-63-5P
	677283-64-6P	677283-65-7P	677283-66-8P	677283-67-9P	677283-68-0P
	677283-69-1P	677283-70-4P	677283-71-5P	677283-72-6P	677283-73-7P
	677283-74-8P	677283-75-9P	677283-76-0P	677283-77-1P	677283-78-2P
	677283-79-3P	677283-80-6P	677283-81-7P	677283-82-8P	677283-83-9P
	677283-84-0P	677283-85-1P	677283-86-2P	677283-87-3P	677283-88-4P
	677283-89-5P	677283-90-8P	677283-91-9P	677283-92-0P	677283-93-1P
	677283-94-2P	677283-95-3P	677283-96-4P	677283-97-5P	677283-98-6P
	677283-99-7P	677284-00-3P	677284-01-4P	677284-02-5P	677284-03-6P
	677284-04-7P	677284-05-8P	677284-06-9P	677284-07-0P	677284-08-1P
	677284-09-2P	677284-10-5P	677284-11-6P	677284-12-7P	677284-13-8P
	677284-14-9P	677284-15-0P	677284-16-1P	677284-17-2P	677284-18-3P
	677284-19-4P	677284-20-7P	677284-21-8P	677284-22-9P	677284-23-0P
	677284-24-1P	677284-25-2P	677284-26-3P	677284-27-4P	677284-28-5P
	677284-29-6P	677284-30-9P	677284-31-0P	677284-32-1P	677284-33-2P
	677284-34-3P	677284-35-4P	677284-36-5P	677284-37-6P	677284-38-7P
	677284-39-8P	677284-40-1P	677284-41-2P	677284-42-3P	677284-43-4P
	677284-44-5P	677284-45-6P	677284-46-7P	677284-47-8P	677284-48-9P
	677284-49-0P	677284-50-3P	677284-51-4P	677284-52-5P	677284-53-6P
	677284-54-7P	677284-55-8P	677284-56-9P	677284-57-0P	677284-58-1P
	677284-59-2P	677284-60-5P	677284-61-6P	677284-62-7P	677284-63-8P
	677284-64-9P	677284-65-0P	677284-66-1P	677284-67-2P	677284-68-3P
	677284-69-4P	677284-70-7P	677284-71-8P	677284-72-9P	677284-73-0P
	677284-74-1P	677284-75-2P	677284-76-3P	677284-77-4P	677284-78-5P
	677284-79-6P	677284-80-9P	677284-81-0P	677284-82-1P	677284-83-2P
	677284-84-3P	677284-85-4P	677284-86-5P	677284-87-6P	677284-88-7P
	677284-89-8P	677284-90-1P	677284-91-2P	677284-92-3P	677284-93-4P
	677284-94-5P	677284-95-6P	677284-96-7P	677284-97-8P	677284-98-9P
	677284-99-0P	677285-00-3P	677285-01-4P	677285-02-5P	677285-03-6P
	677285-04-7P	677285-05-8P	677285-06-9P	677285-07-0P	677285-08-1P
	677285-09-2P	677285-10-5P	677285-11-6P	677285-12-7P	677285-13-8P
	677285-14-9P	677285-15-0P	677285-16-1P	677285-17-2P	677285-18-3P
	677285-19-4P	677285-20-7P	677285-21-8P	677285-22-9P	677285-23-0P
	677285-24-1P	677285-25-2P	677285-26-3P	677285-27-4P	677285-28-5P
	677285-29-6P	677285-30-9P	677285-31-0P	677285-32-1P	677285-33-2P
	677285-34-3P	677285-35-4P	677285-36-5P	677285-37-6P	677285-38-7P
	677285-39-8P	677285-40-1P	677285-41-2P	677285-42-3P	677285-43-4P
	677285-44-5P	677285-45-6P	677285-46-7P	677285-47-8P	677285-48-9P
	677285-49-0P	677285-50-3P	677285-51-4P	677285-52-5P	677285-53-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
for treating cancer)

IT	677285-53-9P	677285-54-0P	677285-55-1P	677285-56-2P	677285-57-3P
	677285-58-4P	677285-59-5P	677285-60-8P	677285-61-9P	677285-62-0P
	677285-63-1P	677285-64-2P	677285-65-3P	677285-66-4P	677285-67-5P
	677285-68-6P	677285-69-7P	677285-70-0P	677285-71-1P	677285-72-2P
	677285-73-3P	677285-74-4P	677285-75-5P	677285-76-6P	677285-77-7P

677285-78-8P	677285-79-9P	677285-80-2P	677285-81-3P	677285-82-4P
677285-83-5P	677285-84-6P	677285-85-7P	677285-86-8P	677285-87-9P
677285-88-0P	677285-89-1P	677285-90-4P	677285-91-5P	677285-92-6P
677285-93-7P	677285-94-8P	677285-95-9P	677285-96-0P	677285-97-1P
677285-98-2P	677285-99-3P	677286-00-9P	677286-01-0P	677286-02-1P
677286-03-2P	677286-04-3P	677286-05-4P	677286-06-5P	677286-07-6P
677286-08-7P	677286-09-8P	677286-10-1P	677286-11-2P	677286-12-3P
677286-13-4P	677286-14-5P	677286-15-6P	677286-16-7P	677286-17-8P
677286-18-9P	677286-19-0P	677286-20-3P	677286-21-4P	677286-22-5P
677286-23-6P	677286-24-7P	677286-25-8P	677286-26-9P	677286-27-0P
677286-28-1P	677286-29-2P	677286-30-5P	677286-31-6P	677286-32-7P
677286-33-8P	677286-34-9P	677286-35-0P	677286-36-1P	677286-37-2P
677286-38-3P	677286-39-4P	677286-40-7P	677286-41-8P	677286-42-9P
677286-43-0P	677286-44-1P	677286-45-2P	677286-46-3P	677286-47-4P
677286-48-5P	677286-49-6P	677286-50-9P	677286-51-0P	677286-52-1P
677286-53-2P	677286-54-3P	677286-55-4P	677286-56-5P	677286-57-6P
677286-58-7P	677286-59-8P	677286-60-1P	677286-61-2P	677286-62-3P
677286-63-4P	677286-64-5P	677286-65-6P	677286-66-7P	677286-67-8P
677286-68-9P	677286-70-3P	677286-71-4P	677286-72-5P	677286-73-6P
677286-74-7P	677286-75-8P	677286-76-9P	677286-77-0P	677286-78-1P
677286-79-2P	677286-80-5P	677286-81-6P	677286-82-7P	677286-83-8P
677286-84-9P	677286-85-0P	677286-86-1P	677286-87-2P	677286-88-3P
677286-89-4P	677286-90-7P	677286-91-8P	677286-92-9P	677286-93-0P
677286-94-1P	677286-95-2P	677286-96-3P	677286-97-4P	677286-98-5P
677286-99-6P	677287-00-2P	677287-01-3P	677287-02-4P	677287-03-5P
677287-04-6P	677287-05-7P	677287-06-8P	677287-07-9P	677287-08-0P
677287-09-1P	677287-10-4P	677287-11-5P	677287-12-6P	677287-13-7P
677287-14-8P	677287-15-9P	677287-16-0P	677287-17-1P	677287-18-2P
677287-19-3P	677287-20-6P	677287-21-7P	677287-22-8P	677287-23-9P
677287-24-0P	677287-25-1P	677287-26-2P	677287-27-3P	677287-28-4P
677287-29-5P	677287-30-8P	677287-31-9P	677287-32-0P	677287-33-1P
677287-34-2P	677287-35-3P	677287-36-4P	677287-37-5P	677287-38-6P
677287-39-7P	677287-40-0P	677287-41-1P	677287-42-2P	677287-43-3P
677287-44-4P	677287-45-5P	677287-46-6P	677287-47-7P	677287-48-8P
677287-49-9P	677287-50-2P	677287-51-3P	677287-52-4P	677287-53-5P
677287-54-6P	677287-55-7P	677287-56-8P	677287-57-9P	677287-58-0P
677287-59-1P	677287-60-4P	677287-61-5P	677287-62-6P	677287-63-7P
677287-64-8P	677287-65-9P	677287-66-0P	677287-67-1P	677287-68-2P
677287-69-3P	677287-70-6P	677287-71-7P	677287-72-8P	677287-73-9P
677287-74-0P	677287-75-1P	677287-76-2P	677287-77-3P	677287-78-4P
677287-79-5P	677287-80-8P	677287-81-9P	677287-82-0P	677287-83-1P
677287-84-2P	677287-85-3P	677287-86-4P	677287-87-5P	

RL: PAC (Pharmacological activity); SPN (Synthetic Preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
for treating cancer)

IT	677287-88-6P	677287-89-7P	677287-90-0P	677287-91-1P	677287-92-2P
	677287-93-3P	677287-94-4P	677287-95-5P	677287-96-6P	677287-97-7P
	677287-98-8P	677287-99-9P	677288-00-5P	677288-01-6P	677288-02-7P
	677288-03-8P	677288-04-9P	677288-05-0P	677288-06-1P	677288-07-2P
	677288-08-3P	677288-09-4P	677288-10-7P	677288-11-8P	677288-12-9P
	677288-13-0P	677288-14-1P	677288-15-2P	677288-16-3P	677288-17-4P
	677288-18-5P	677288-19-6P	677288-20-9P	677288-21-0P	677288-22-1P
	677288-23-2P	677288-24-3P	677288-25-4P	677288-26-5P	677288-27-6P
	677288-28-7P	677288-29-8P	677288-30-1P	677288-31-2P	677288-32-3P
	677288-33-4P	677288-34-5P	677288-35-6P	677288-36-7P	677288-37-8P
	677288-38-9P	677288-39-0P	677288-40-3P	677288-41-4P	677288-42-5P
	677288-43-6P	677288-44-7P	677288-45-8P	677288-46-9P	677288-47-0P
	677288-48-1P	677288-49-2P	677288-50-5P	677288-51-6P	677288-52-7P
	677288-53-8P	677288-54-9P	677288-55-0P	677288-56-1P	677288-57-2P
	677288-58-3P	677288-59-4P	677288-60-7P	677288-61-8P	677288-62-9P

677288-63-0P	677288-64-1P	677288-65-2P	677288-66-3P	677288-67-4P
677288-68-5P	677288-69-6P	677288-70-9P	677288-71-0P	677288-72-1P
677288-73-2P	677288-74-3P	677288-75-4P	677288-76-5P	677288-77-6P
677288-78-7P	677288-79-8P	677288-80-1P	677288-81-2P	677288-82-3P
677288-83-4P	677288-84-5P	677288-85-6P	677288-86-7P	677288-87-8P
677288-88-9P	677288-89-0P	677288-90-3P	677288-91-4P	677288-92-5P
677288-93-6P	677288-94-7P	677288-95-8P	677288-96-9P	677288-97-0P
677288-98-1P	677288-99-2P	677289-00-8P	677289-01-9P	677289-02-0P
677289-03-1P	677289-04-2P	677289-05-3P	677289-06-4P	677289-07-5P
677289-08-6P	677289-09-7P	677289-10-0P	677289-11-1P	677289-12-2P
677289-13-3P	677289-14-4P	677289-15-5P	677289-16-6P	677289-17-7P
677289-18-8P	677289-19-9P	677289-20-2P	677289-21-3P	677289-22-4P
677289-23-5P	677289-24-6P	677289-25-7P	677289-26-8P	677289-27-9P
677289-28-0P	677289-29-1P	677289-30-4P	677289-31-5P	677289-32-6P
677289-33-7P	677289-34-8P	677289-35-9P	677289-36-0P	677289-37-1P
677289-38-2P	677289-39-3P	677289-40-6P	677289-41-7P	677289-42-8P
677289-43-9P	677289-44-0P	677289-45-1P	677289-46-2P	677289-47-3P
677289-48-4P	677289-49-5P	677289-50-8P	677289-51-9P	677289-52-0P
677289-53-1P	677289-54-2P	677289-55-3P	677289-56-4P	677289-57-5P
677289-58-6P	677289-59-7P	677289-60-0P	677289-61-1P	677289-62-2P
677289-63-3P	677289-64-4P	677289-65-5P	677289-66-6P	677289-67-7P
677289-68-8P	677289-69-9P	677289-70-2P	677289-71-3P	677289-72-4P
677289-73-5P	677289-74-6P	677289-75-7P	677289-76-8P	677289-77-9P
677289-78-0P	677289-79-1P	677289-80-4P	677289-81-5P	677289-82-6P
677289-83-7P	677289-84-8P	677289-85-9P	677289-86-0P	677289-87-1P
677289-88-2P	677289-89-3P	677289-90-6P	677289-91-7P	677289-92-8P
677289-93-9P	677289-94-0P	677289-95-1P	677289-96-2P	677289-97-3P
677289-98-4P	677289-99-5P	677290-00-5P	677290-01-6P	677290-02-7P
677290-03-8P	677290-04-9P	677290-05-0P	677290-06-1P	677290-07-2P
677290-08-3P	677290-09-4P	677290-10-7P	677290-11-8P	677290-12-9P
677290-13-0P	677290-14-1P	677290-15-2P	677290-16-3P	677290-17-4P
677290-18-5P	677290-19-6P	677290-20-9P	677290-21-0P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
for treating cancer)

IT 677290-22-1P 677290-23-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
for treating cancer)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> d 16 1-27 ibib abs hitstr

L6 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2008:1300802 CAPLUS

DOCUMENT NUMBER: 149:513860

TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent
kinase inhibitors




INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.;
Doll, Ronald; Girijavallabhan, Viyyoor M.; Mallams,
Alan; Alvarez, Carmen S.; Keertikar, Kartik M.;
Rivera, Jocelyn; Chan, Tin-Yau; Madison, Vincent S.;
Fischmann, Thierry O.; Kirschmeier, Paul; Bannerji,
Rajat; Dillard, Lawrence W.; Tran, Vinh D.; He,
Zhenmin; James, Ray Anthony; Park, Haengsoon;
Paradkar, Vidyadhar M.; Hobbs, Douglas W.

PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacopeia, Inc.

SOURCE: PCT Int. Appl., 635pp.
 DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English
 PATENT INFORMATION: 10

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008130570	A1	20081030	WO 2008-US4907	20080416
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 20080050384	A1	20080228	US 2007-788847	20070420
PRIORITY APPLN. INFO.:			US 2007-788847	A 20070420
			US 2002-408027P	P 20020904
			US 2002-421959P	P 20021029
			US 2003-654546	A2 20030903
			US 2004-776988	A3 20040211
			US 2006-396079	B2 20060331

OTHER SOURCE(S): MARPAT 149:513860
 GI



AB The title compds. [I; R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared. Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μ M and 0.029 μ M against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical compns. comprising the compound I alone or in combination with other therapeutic agents are claimed.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1300618 CAPLUS

DOCUMENT NUMBER: 149:513859

TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors

INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Labroli, Marc; Keertikar, Kartik M.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 723pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English




FAMILY ACC. NUM. COUNT: 10

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008130569	A1	20081030	WO 2008-US4906	20080416
W:	AE, AG, AL, AM, AO, AT, AU, AZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 20070281951	A1	20071206	US 2007-788856	20070420
PRIORITY APPLN. INFO.:			US 2007-788856	A 20070420
			US 2002-408027P	P 20020904
			US 2002-421959P	P 20021029
			US 2003-654546	A2 20030903
			US 2004-776988	A2 20040211
			US 2005-245401	A3 20051006
			US 2007-710644	A2 20070223

OTHER SOURCE(S): MARPAT 149:513859

GI



AB The title compds. [I; R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared. Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μ M and 0.029 μ M against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I, alone or in combination with other therapeutic agent, is claimed.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:251311 CAPLUS

DOCUMENT NUMBER: 148:308364

TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors

INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Mallams, Alan; Alvarez, Carmen S.; Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-Yau; Madison, Vincent S.; Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhenmin; James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs, Douglas Walsh; Kirschmeier, Paul; Bannerji, Rajat

PATENT ASSIGNEE(S): Shering Corporation and Pharmacoepia, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 387 pp., Cont.-in-part of U.S. Ser. No. 396,079.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English




FAMILY ACC. NUM. COUNT: 10

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080050384	A1	20080228	US 2007-788847	20070420
CN 1880317	A	20061220	CN 2006-10101322	20030903
US 7161003	B2	20070109	US 2003-654546	20030903
US 20070037824	A1	20070215		
US 20040209878	A1	20041021	US 2004-776988	20040211
US 7119200	B2	20061010		
ZA 2005001855	A	20060329	ZA 2005-1855	20060117
US 20070054925	A1	20070308	US 2006-396079	20060331
WO 2008130570	A1	20081030	WO 2008-US4907	20080416
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:
 US 2002-408027P P 20020904
 US 2002-421959P P 20021029
 US 2003-654546 A2 20030903
 US 2004-776988 A3 20040211
 US 2006-396079 B2 20060331
 CN 2003-824997 A3 20030903
 US 2007-788847 A 20070420

OTHER SOURCE(S): MARPAT 148:308364
 GI



AB The title compds. [I; R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared. Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μ M and 0.029 μ M against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical compns. comprising the compound I alone or in combination with other therapeutic agents are claimed.




L6 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2007:1395785 CAPLUS
DOCUMENT NUMBER: 148:55084
TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Labroli, Marc; Keertikar, Kartik M.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 497pp., Cont.-in-part of U.S. Ser. No. 710,644.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070281951	A1	20071206	US 2007-788856	20070420
CN 1880317	A	20061220	CN 2006-10101322	20030903
US 7161003	B2	20070109	US 2003-654546	20030903
US 20070037824	A1	20070215		
US 20040209878	A1	20041021	US 2004-776988	20040211
US 7119200	B2	20061010		
US 20060128725	A1	20060615	US 2005-245401	20051006
US 7196078	B2	20070327		
ZA 2005001855	A	20060329	ZA 2005-1855	20060117
US 20070225270	A1	20070927	US 2007-710644	20070223
WO 2008130569	A1	20081030	WO 2008-US4906	20080416
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:
US 2002-408027P P 20020904
US 2002-421959P P 20021029
US 2003-654546 A2 20030903
US 2004-776988 A2 20040211
US 2005-245401 A3 20051006
US 2007-710644 A2 20070223
CN 2003-824997 A3 20030903
US 2007-788856 A 20070420

OTHER SOURCE(S): MARPAT 148:55084
GI




AB The title compds. [I; R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared. Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μ M and 0.029 μ M against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I, alone or in combination with other therapeutic agent, is claimed.

L6 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:1179520 CAPLUS
 DOCUMENT NUMBER: 147:469333
 TITLE: Inhibition of raf kinase using substituted heterocyclic ureas
 INVENTOR(S): Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Paulsen, Holger; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Hatoum-Mokdad, Holia; Johnson, Jeffrey; Lee, Wendy; Redman, Aniko; Sibley, Robert; Renick, Joel
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 111pp., Div. of U.S. Ser. No. 640,780.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

US 20070244120 A1 20071018 US 2007-768112 20070625 <--
 PRIORITY APPLN. INFO.: US 2000-640780 A3 20000818 <--
 OTHER SOURCE(S): MARPAT 147:469333
 GI




AB A method for treatment of cancerous cell growth mediated by raf kinase comprises administration of urea derivs. ANHCONHB [I; A = substituted isoxazolyl, thienyl, thiadiazolyl, furyl, pyrazolyl, etc.; B = (substituted) mono-, di-, or tricyclic aryl, heteroaryl containing ≥ 1 5-6 membered aromatic structure containing 0-4 N, O, or S atoms]. Reaction of 4-phenoxyphenyl isocyanate with 5-amino-3-tert-butylisoxazole in methylene chloride and heating at reflux temperature for 2 days gave 70% II. In an in vitro raf kinase assay, I displayed IC50 values of 1-10 μM .

IT 228999-76-6P 229000-21-9P 229000-25-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of substituted heterocyclic ureas for treatment of cancerous cell growth mediated by raf kinase)


RN 228999-76-6 CAPLUS

CN Benzamide, 3-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-phenyl- (CA INDEX NAME)



RN 229000-21-9 CAPLUS


CN Benzamide, 3-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-(4-fluorophenyl)- (CA INDEX NAME)



RN 229000-25-3 CAPLUS

CN Benzamide, 3-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)

INDEX NAME)



L6 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:691680 CAPLUS

DOCUMENT NUMBER: 147:118041

TITLE: Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

INVENTOR(S): Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-Katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA

SOURCE: U.S., 52pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 7235576	B1	20070626	US 2002-42203	20020111 <--
US 20030144278	A1	20030731	US 2002-283248	20021030 <--
US 20080108672	A1	20080508	US 2007-768104	20070625 <--
PRIORITY APPLN. INFO.:			US 2001-367380P	P 20010112 <--
			US 2002-42203	A1 20020111 <--

OTHER SOURCE(S): MARPAT 147:118041

AB Aryl ureas A-NHCONH-B [A, B = C5-40 (poly)aryl, optionally containing 0-4 N, O, S heteroatoms, optionally substituted by (hetero)aryl, (hetero)aryloxy, halo, cyano, nitro, alkoxy, alkylthio, amino, hydroxyalkyl, sulfo, acyl, carboxamido-groups], useful as Raf-kinase inhibitors for treatment and inhibition of cancerous cell growth, were prepared by standard

synthetic procedures by reactions of the corresponding isocyanates with aromatic amines and tested for inhibition of Raf kinase and growth of human tumor cell lines HCT116 and DLD-1, exhibiting IC50 values of 1 nM to 10 μM. In an example, N-(4-chloro-3-trifluoromethylphenyl)-N'-[4-(2-methylaminocarbonyl-4-pyridinyloxy)phenyl]urea was prepared by reaction of 65.9 mmol of 4-chloro-3-trifluoromethylphenyl isocyanate with 65.77 mmol of 4-(2-methylaminocarbonyl-4-pyridinyloxy)aniline in CH2Cl2 at room temperature

for 22 h with 93% yield.

IT 284461-67-2P 284461-68-3P 284461-70-7P

284462-09-5P 284462-10-8P 284462-15-3P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);


BIOL (Biological study); PREP (Preparation)

(preparation of carboxyaryl-substituted diarylureas as Raf kinase inhibitors for treatment and inhibition of cancerous cell growth)

RN 284461-67-2 CAPLUS


CN Benzamide, N-(4-fluorophenyl)-3-[4-[[[2-methoxy-5-

(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-68-3 CAPLUS

CN Benzamide, N-[4-(dimethylamino)phenyl]-3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-70-7 CAPLUS

CN Benzamide, 3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 284462-09-5 CAPLUS

CN Benzamide, 3-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(4-fluorophenyl)- (CA INDEX NAME)




RN 284462-10-8 CAPLUS

CN Benzamide, 3-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(4-dimethylaminophenyl)- (CA INDEX NAME)



RN 284462-15-3 CAPLUS
 CN Benzamide, 3-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 223 THERE ARE 223 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:962905 CAPLUS

DOCUMENT NUMBER: 147:211873

TITLE: Preparation of substituted heterocyclic ureas for inhibition of raf kinase

INVENTOR(S): Scott, William J.; Redman, Aniko; Johnson, Jeffrey; Wood, Jill E.; Paulsen, Holger; Khire, Uday; Dumas, Jacques; Smith, Roger A.; Lee, Wendy; Hatoum-Mokdad, Holia; Riedl, Bernd; Lowinger, Timothy Bruno

PATENT ASSIGNEE(S): Bayer Corporation, USA

SOURCE: Aust. Pat. Appl., 148 pp., Division of Austl. 2003 204708.

CODEN: AUXXCM

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
AU 2006201959	A1	20060601	AU 2006-201959	20060511 <--
AU 2006201959	B2	20080904		
AU 2003204708	A1	20030717	AU 2003-204708	20030613 <--
AU 2003204708	B2	20060525		
PRIORITY APPLN. INFO.:			AU 2003-204708	A3 20030613 <--
			AU 1999-21989	A3 19981222 <--
			WO 1998-US26078	W 19981222 <--

OTHER SOURCE(S): MARPAT 147:211873
 GI



AB The title compds. ANHC(O)NHB [I; A = (un)substituted pyrazolyl, isoxazolyl, thienyl, etc.; B = (un)substituted Ph, pyridinyl, indolinyl, isouinolyl, etc.], useful in treating raf mediated diseases such as cancer, were prepared Thus, reacting 5-tert-butyl-3-thiophene-ammonium chloride with 4-phenoxyphenyl isocyanate in DMF afforded II. All exemplified compds. I displayed IC50 of between 1 nM and 10 μM when tested in in vitro raf kinase assay. Pharmaceutical composition comprising the compound I is disclosed.


IT 228999-76-6P 229000-21-9P 229000-25-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted heterocyclic ureas for inhibition of raf kinase)


RN 228999-76-6 CAPLUS

CN Benzamide, 3-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-phenyl- (CA INDEX NAME)




RN 229000-21-9 CAPLUS

CN Benzamide, 3-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-(4-fluorophenyl)- (CA INDEX NAME)



RN 229000-25-3 CAPLUS

CN Benzamide, 3-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



L6 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:579598 CAPLUS
DOCUMENT NUMBER: 145:62916
TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent
kinase inhibitors
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.;
Labroli, Marc; Keertikar, Kartik M.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 1068 pp., Cont.-in-part of U.S.
Ser. No. 776,988.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:




PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060128725	A1	20060615	US 2005-245401	20051006
US 7196078	B2	20070327		
CN 1880317	A	20061220	CN 2006-10101322	20030903
US 7161003	B2	20070109	US 2003-654546	20030903
US 20070037824	A1	20070215		
US 20040209878	A1	20041021	US 2004-776988	20040211
US 7119200	B2	20061010		
ZA 2005001855	A	20060329	ZA 2005-1855	20060117
US 20070072881	A1	20070329	US 2006-542920	20061004
AU 2006302443	A1	20070419	AU 2006-302443	20061004
CA 2624829	A1	20070419	CA 2006-2624829	20061004
WO 2007044449	A2	20070419	WO 2006-US38939	20061004
WO 2007044449	A3	20070524		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, ES, EE, EG, EI, FI, GB, GE, GH, GM, HN, HR, HU, ID, IL, IN, JP, KE, KG, KM, KN, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GQ, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, CA			
EP 1931677	A2	20080618	EP 2006-836186	20061004
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
US 20070225270	A1	20070927	US 2007-710644	20070223
US 20070281951	A1	20071206	US 2007-788856	20070420
IN 2008CN01697	A	20081226	IN 2008-CN1697	20080404
MX 200804665	A	20080617	MX 2008-4665	20080407

KR 2008063796
CN 101321756
PRIORITY APPLN. INFO.:

A 20080707
A 20081210

KR 2008-710183 20080428
CN 2006-80045338 20080602
US 2002-408027P P 20020904
US 2002-421959P P 20021029
US 2003-654546 A2 20030903
US 2004-776988 A2 20040211
CN 2003-824997 A3 20030903
US 2005-245401 A2 20051006
WO 2006-US38939 W 20061004
US 2007-710644 A2 20070223

OTHER SOURCE(S): MARPAT 145:62916
GI



AB The title compds. [I; R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared. Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μ M and 0.029 μ M against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I is claimed.

REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2005:470258 CAPLUS

DOCUMENT NUMBER: 143:1330

TITLE: Amide derivatives as kinase modulators, and their therapeutic use

INVENTOR(S): Mehta, Shamal A.; Grotzfeld, Robert M.; Milanov, Zdravko V.; Andiliy, Lai G.; Patel, Hitesh K.; Lockhart, David J.

PATENT ASSIGNEE(S): Ambit Biosciences Corporation, USA
 SOURCE: PCT Int. Appl., 208 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005048953	A2	20050602	WO 2004-US38433	20041115 <--
WO 2005048953	A3	20060223		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20050148605	A1	20050707	US 2004-989745	20041115 <--
US 20050165031	A1	20050728	US 2004-989814	20041115 <--
US 20050165024	A1	20050728	US 2004-989824	20041115 <--
US 20050165074	A1	20050728	US 2004-990007	20041115 <--
US 20050171171	A1	20050804	US 2004-989766	20041115 <--
US 20050171172	A1	20050804	US 2004-989823	20041115 <--
US 20050192314	A1	20050901	US 2004-990195	20041115 <--
US 20050197371	A1	20050908	US 2004-990194	20041115 <--
US 20050261315	A1	20051124	US 2004-989623	20041115 <--
US 20050267182	A1	20051201	US 2004-989717	20041115 <--
PRIORITY APPLN. INFO.:			US 2003-520273P	P 20031113 <--
			US 2003-527094P	P 20031203 <--
			US 2003-531082P	P 20031218 <--
			US 2003-531243P	P 20031218 <--

OTHER SOURCE(S): MARPAT 143:1330

AB The invention provides methods and compns. for treating conditions mediated by various kinases wherein derivs. of amide compds. are employed. The invention also provides methods of using the compds. and/or compns. in the treatment of a variety of diseases and unwanted conditions in subjects. Preparation of N-(3-tert-butylisoxazol-5-yl)-2-[4-(benzyloxy)phenyl]acetamide is described.


IT 1044667-71-1

RL: PRPH (Prophetic)

(Amide derivatives as kinase modulators, and their therapeutic use)

RN 1044667-71-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



L6 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:369222 CAPLUS

DOCUMENT NUMBER: 142:430279

TITLE: Preparation of aminofurazanyl imidazopyridines as Rho kinase inhibitors

INVENTOR(S): Lee, Dennis; Stavenger, Robert A.; Goodman, Krista B.; Hilfiker, Mark A.; Cui, Haifeng; Viet, Andrew Q.

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 143 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005037197	A2	20050428	WO 2004-US32824	20041006 <--
WO 2005037197	A3	20050602		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1675552	A2	20060705	EP 2004-794238	20041006 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR			
JP 2007507546	T	20070329	JP 2006-534264	20041006 <--
US 20080234261	A1	20080925	US 2006-574676	20060404 <--
PRIORITY APPLN. INFO.:			US 2003-508894P	P 20031006 <--
			US 2003-531949P	P 20031223 <--
			WO 2004-US32824	W 20041006
OTHER SOURCE(S):	CASREACT 142:430279; MARPAT 142:430279			
GI				



AB Title compds. I [wherein X = (un)substituted NH, O, S, SO or SO₂; R₁, R₂ = (un)substituted alkyl, Ph, heteroaryl, etc.; and physiol. acceptable salts thereof] were prepared as Rho-kinase inhibitors. For example, 2,4-dichloro-5-nitropyridine (preparation given) underwent substitution with aniline (71% yield) and 3-acetylaminophenol (97% yield) subsequently followed by nitro reduction with H₂ in the presence of Pd/C to give II (100% yield). Conversion of this compound into III was realized via EDCI-mediated coupling with cyanoacetic acid, thermal intramol. cyclization to an 2-imidazoacetonitrile (65% yield for the two steps), reaction with NaNO₂-HCl in methanol to an oxime (95% yield), and cyclization with NH₂OH in the presence of Et₃N (40% yield). The invented compds. are useful for the treatment of diseases, such as hypertension, heart failure and ischemic angina.


IT 8506665-83-7P, N-[4-(Aminomethyl)phenyl]-3-[[2-(4-aminofuran-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzamide
850666-20-5P, 3-[[2-(4-Aminofuran-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-(methyloxy)phenyl]benzamide 850666-21-6P
3-[[2-(4-(4-Aminofuran-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-(dimethylamino)phenyl]benzamide 850666-22-7P,
3-[[2-(4-Aminofuran-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(dimethylamino)phenyl]benzamide 850666-35-2P,
3-[[2-(4-Aminofuran-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-(dimethylamino)phenyl]benzamide 850666-37-4P,
3-[[2-(4-Aminofuran-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-(4-morpholinyl)phenyl]benzamide 850666-39-6P,
3-[[2-(4-Aminofuran-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-(methyloxy)phenyl]benzamide 850666-58-9P,
3-[[2-(4-Aminofuran-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[[2-(4-morpholinyl)ethyl]oxy]phenyl]benzamide 850666-73-8P,
3-[[2-(4-Aminofuran-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[[2-(dimethylamino)ethyl]oxy]phenyl]benzamide 850666-75-0P,
3-[[2-(4-Aminofuran-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[[3-(dimethylamino)propyl]oxy]phenyl]benzamide 850666-82-9P,
N-[4-(Acetylamino)phenyl]-3-[[2-(4-aminofuran-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzamide 850666-84-1P,
N-[4-(Aminocarbonyl)phenyl]-3-[[2-(4-aminofuran-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzamide 850667-16-2P,
3-[[2-(4-Aminofuran-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[[1,1-dioxido-4-thiomorpholinyl]methyl]phenyl]benzamide
850667-36-6P, 3-[[2-(4-Aminofuran-3-yl)-1-ethyl-1H-imidazo[4,5-

c[pyridin-6-yl]oxy]-N-[4-[(dimethylamino)methyl]phenyl]benzamide
 850667-37-7P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-
 c]pyridin-6-yl]oxy]-N-[4-[2-(dimethylamino)ethyl]phenyl]benzamide
 850667-38-8P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-
 c]pyridin-6-yl]oxy]-N-[4-[2-(1-pyrrolidinyl)ethyl]phenyl]benzamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(inhibitor; preparation of aminofurazanyl imidazopyridines as Rho
 kinase inhibitors)


RN 850665-83-7 CAPLUS

CN Benzamide, N-[4-(aminomethyl)phenyl]-3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-
 1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]- (CA INDEX NAME)




RN 850666-20-5 CAPLUS

CN Benzamide, N-[4-(aminomethyl)phenyl]-3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-
 c]pyridin-6-yl]oxy]-N-(4-methoxyphenyl)- (CA INDEX NAME)




RN 850666-21-6 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-
 c]pyridin-6-yl]oxy]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 850666-22-7 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-
 c]pyridin-6-yl]oxy]-N-[3-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 850666-35-2 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 850666-37-4 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 850666-39-6 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-(4-methoxyphenyl)- (CA INDEX NAME)




RN 850666-58-9 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)




RN 850666-73-8 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[2-(dimethylamino)ethoxy]phenyl]- (CA INDEX NAME)




RN 850666-75-0 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[3-(dimethylamino)propoxy]phenyl]- (CA INDEX NAME)




RN 850666-82-9 CAPLUS

CN Benzamide, N-[4-(acetamino)phenyl]-3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]- (CA INDEX NAME)




RN 850666-84-1 CAPLUS

CN Benzamide, N-[4-(aminocarbonyl)phenyl]-3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]- (CA INDEX NAME)




RN 850667-16-2 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[(1,1-dioxido-4-thiomorpholinyl)methyl]phenyl]- (CA INDEX NAME)




RN 850667-36-6 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[(dimethylamino)methyl]phenyl]- (CA INDEX NAME)




RN 850667-37-7 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[2-(dimethylamino)ethyl]phenyl]- (CA INDEX NAME)



RN 850667-38-8 CAPLUS


CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[2-(1-pyrrolidinyl)ethyl]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:29239 CAPLUS
 DOCUMENT NUMBER: 142:134619
 TITLE: Preparation of pyridinyl/pyridazinylloxymethyl substituted Raf kinase inhibitors
 INVENTOR(S): Gill, Adrian Liam; Woodhead, Steven John; Woodhead, Andrew James; Frederickson, Martyn; Padova, Alessandro; Apaya, Robert Patrick
 PATENT ASSIGNEE(S): Astex Technology Limited, UK
 SOURCE: PCT Int. Appl., 143 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005002673	A1	20050113	WO 2004-GB2877	20040702 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2003-484300P	P 20030703 <--
			US 2003-484301P	P 20030703 <--
OTHER SOURCE(S):			MARPAT 142:134619	
GI				



AB Title compds. I [X=Y=CR2=CR3, CR2=N; R1=H, halo, amino, etc.; R2-3=H, alkyl, aryl, etc.; R4=carboaryl, heteroaryl, etc.; R5=halo, amino, etc.] are prepared For instance, 2-amino-3-benzoyloxypyridine is prepared from 2-amino-3-hydroxypyridine and benzyl chloride. Over 180 examples are

provided. Selected example compds. have an IC50 < 1 μ M for B-Raf kinase. I are useful in the treatment of a condition ameliorated by the inhibition of raf kinase, e.g., cancer.


IT 642085-16-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridinyl/pyridazinyloxymethyl substituted Raf kinase inhibitors)

RN 642085-16-3 CAPLUS

CN Benzamide, N-[4-fluoro-3-[(2-pyrazinyloxy)methyl]phenyl]-3-phenoxy- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:1154653 CAPLUS

DOCUMENT NUMBER: 142:93545

TITLE: Preparation of diaryl ureas with kinase inhibiting activity

INVENTOR(S): Wilhelm, Scott; Dumas, Jacques; Ladouceur, Gaetan; Lynch, Mark; Scott, William J.

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA

SOURCE: PCT Int. Appl., 122 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113274	A2	20041229	WO 2004-US15655	20040519 <--
WO 2004113274	A3	20050303		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RN:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2526617	A1	20041229	CA 2004-2526617	20040519 <--
US 20050059703	A1	20050317	US 2004-848567	20040519 <--
EP 1636585	A2	20060322	EP 2004-752642	20040519 <--
EP 1636585	B1	20080116		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
JP 2007511203	T	20070510	JP 2006-533211	20040519 <--
AT 366108	T	20070715	AT 2004-776037	20040519 <--


ES 2288694	T3	20080116	ES 2004-776037	20040519 <--
AT 384264	T	20080215	AT 2004-752642	20040519 <--
ES 2305808	T3	20081101	ES 2004-752642	20040519 <--
MX 2005PA12491	A	20060929	MX 2005-PA12491	20051118 <--
US 20070020704	A1	20070125	US 2006-571100	20060728 <--
PRIORITY APPLN. INFO.:			US 2003-471735P	P 20030520 <--
			US 2003-520399P	P 20031117 <--
			US 2004-556062P	P 20040325
			WO 2004-US15655	W 20040519

OTHER SOURCE(S): MARPAT 142:93545
GI




AB Diaryl ureas B-NH-CO-NH-L-(CH₂)_m-X-(CH₂)_p-L₁-(Q)1-3 [I; B = (un)substituted Ph, naphthyl, or heteroaryl; L, = (un)substituted Ph, naphthyl, or heteroaryl; X = bond, O, CO, NR₃, NR₃CO, S, CONR₃, CF₂, CCl₂, CHF, CH(OH), C.tplbond.C, CH:CH, CR₄R₅; m, p = independently 0-4; L₁ = any group L, 5-6 membered cyclic structure; Q = independently COR₄, CO₂R₄, CONR₄R₅; each R₃-R₅ = independently H, (un)substituted C1-5 alkyl, C3-5 cycloalkyl, Ph, C1-3 alkylphenyl, C0-4 alkylheteroaryl], useful to treat diseases and conditions associated with signal transduction pathways comprising of at least one of raf, VEGFR, PDGFR, p38 and/or FLT-3. E.g., a multi-step synthesis of the urea II which produced dose-dependent 45-68% inhibition of tumor growth in a staged HCT 116 colon (mutant k-Ras) xenograft model.

IT 284461-67-2P 284461-68-3P 284461-70-7P
284461-71-8P 284462-09-5P 284462-10-8P
284462-15-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diaryl ureas with kinase inhibiting activity)
RN 284461-67-2 CAPLUS
CN Benzamide, N-[4-(4-fluorophenyl)-3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-68-3 CAPLUS
CN Benzamide, N-[4-(dimethylamino)phenyl]-3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-70-7 CAPLUS

CN Benzamide, 3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 284461-71-8 CAPLUS

CN Benzamide, 3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-[4-(2-pyridinyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)




RN 284462-09-5 CAPLUS

CN Benzamide, 3-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(4-fluorophenyl)- (CA INDEX NAME)




RN 284462-10-8 CAPLUS

CN Benzamide, 3-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)



RN 284462-15-3 CAPLUS
 CN Benzamide, 3-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:1038664 CAPLUS

DOCUMENT NUMBER: 142:6556

TITLE: Preparation of substituted heterocycles for the treatment of abnormal cell growth
 INVENTOR(S): Bhattacharya, Samit Kumar; Chen, Jinshan; Connell, Richard Damian; Kath, John Charles; Kauffman, Goss S.; Lipka, Blaise S.; Morris, Joel

PATENT ASSIGNEE(S): Pfizer Inc, USA

SOURCE: U.S. Pat. Appl. Publ., 54 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040242604	A1	20041202	US 2004-849707	20040520 <--
CA 2527017	A1	20041209	CA 2004-2527017	20040517 <--
WO 2004106308	A1	20041209	WO 2004-1B1687	20040517 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

EP 1636195 A1 20060322 EP 2004-733400 20040517 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
 BR 2004010720 A 20060620 BR 2004-10720 20040517 <--
 JP 2007501854 T 20070201 JP 2006-530679 20040517 <--
 MX 2005PA12839 A 20060517 MX 2005-PA12839 20051128 <--
 PRIORITY APPLN. INFO.: US 2003-473817P P 20030527 <--
 WO 2004-1B1687 W 20040517
 OTHER SOURCE(S): CASREACT 142:6556; MARPAT 142:6556
 GI




AB Title compds. I [Z = CR1, CCN, N; A = fused 5-7-membered ring optionally containing heteroatoms; R1 = H, alkyl; m = 0-3; p = 0-4; R3 = Ph, 4-6-membered heterocyclic ring; R4 = substituted divalent alkyl, etc.; R11 = halo, CN, NO2, etc.] are prepared For instance,
 N-tert-Butyl-4-[[2-methyl-4-[(6-(morpholin-4-yl)pyrido[3,4-d]pyrimidin-4-yl)amino]phenyl]oxy]benzamide is prepared in 8 steps from
 6-fluoro-3H-pyrido[3,4-d]pyrimidin-4-one and
 3-(4-amino-2-methylphenoxy)benzoic acid tert-Bu ester. Compds. of the invention have IC50 values of <10 µM against erbB-2 kinase. I are useful for treating abnormal cell growth.

IT 799242-89-0P, 3-[[4-[(6,7-Dimethoxyquinazolin-4-yl)amino]-2-methylphenyl]oxy]-N-(4-methoxyphenyl)benzamide 799242-90-3P, 3-[[4-[(6,7-Dimethoxyquinazolin-4-yl)amino]-2-methylphenyl]oxy]-N-(2-fluorophenyl)benzamide 799243-27-9P, N-(2-Fluorophenyl)-3-[[2-methyl-4-[(6-(morpholin-4-yl)pyrido[3,4-d]pyrimidin-4-yl)amino]phenyl]oxy]benzamide 799243-38-2P, N-(2-Fluorophenyl)-3-[[2-methyl-4-[(6-[(2-(morpholin-4-yl)ethyl)amino]pyrido[3,4-d]pyrimidin-4-yl)amino]phenyl]oxy]benzamide 799243-43-9P, N-(2-Fluorophenyl)-3-[[2-methyl-4-[(6-(4-methylpiperazin-1-yl)pyrido[3,4-d]pyrimidin-4-yl)amino]phenyl]oxy]benzamide 799243-47-3P, N-(2-Fluorophenyl)-3-[[2-methyl-4-[(6-(pyrrolidin-1-yl)pyrido[3,4-d]pyrimidin-4-yl)amino]phenyl]oxy]benzamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of substituted pyrimidine/quinazolines for treatment of abnormal cell growth)


RN 799242-89-0 CAPLUS

CN Benzamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-methylphenoxy]-N-(4-methoxyphenyl)- (CA INDEX NAME)




RN 799242-90-3 CAPLUS

CN Benzamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-methylphenoxy]-N-(2-fluorophenyl)- (CA INDEX NAME)




RN 799243-27-9 CAPLUS

CN Benzamide, N-(2-fluorophenyl)-3-[2-methyl-4-[[6-(4-morpholinyl)pyrido[3,4-d]pyrimidin-4-yl]amino]phenoxy]- (CA INDEX NAME)




RN 799243-38-2 CAPLUS

CN Benzamide, N-(2-fluorophenyl)-3-[2-methyl-4-[[6-[[2-(4-morpholinyl)ethyl]amino]pyrido[3,4-d]pyrimidin-4-yl]amino]phenoxy]- (CA INDEX NAME)




RN 799243-43-9 CAPLUS

CN Benzamide, N-(2-fluorophenyl)-3-[2-methyl-4-[[6-(4-methyl-1-piperazinyl)pyrido[3,4-d]pyrimidin-4-yl]amino]phenoxy]- (CA INDEX NAME)



RN 799243-47-3 CAPLUS
 CN Benzamide, N-(2-fluorophenyl)-3-[2-methyl-4-[[6-(1-pyrrolidinyl)pyrido[3,4-d]pyrimidin-4-yl]amino]phenoxy]- (CA INDEX NAME)






L6 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2004:980998 CAPLUS
 DOCUMENT NUMBER: 141:379942
 TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
 INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Mallams, Alan; Alvarez, Carmen S.; Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-Yau; Madison, Vincent; Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs, Douglas Walsh

PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacoepia, Inc.
 SOURCE: U.S. Pat. Appl. Publ., 1044 pp., Cont.-in-part of U.S. Ser. No. 654,546.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040209878	A1	20041021	US 2004-776988	20040211 <--
US 20040209878	A1	20041021	US 2004-776988	20040211 <--
PRIORITY APPLN. INFO.:			US 2002-408027P	P 20020904 <--
			US 2002-421959P	P 20021029 <--
			US 2003-654546	A2 20030903 <--
			US 2004-776988	A 20040211

GI



AB The title compds. [I R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared. Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μ M and 0.029 μ M against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I is claimed. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]


IT 677786-82-2P 677787-26-7P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

RN 677786-82-2 CAPLUS

CN Benzamide, N-[4-[[[3-bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]methyl]phenyl]-3-phenoxy- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 677787-26-7 CAPLUS

CN Benzamide, N-[3-[[[3-bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]methyl]phenyl]-3-phenoxy- (CA INDEX NAME)



L6 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:265847 CAPLUS

DOCUMENT NUMBER: 140:321370

TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors

INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viiyoor Moopil; Mallams, Alan; Alvarez, Carmen S.; Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-yau; Madison, Vincent; Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs, Douglas Walsh

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 609 pp.

CODEN: PIXXD2




DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 10

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022561	A1	20040318	WO 2003-XA27555	20030903 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CN 1735614	A	20060215	CN 2003-824997	20030903 <--
CN 100376580	C	20080326		
CN 1880317	A	20061220	CN 2006-10101322	20030903 <--
ZA 2005001855	A	20060329	ZA 2005-1855	20060117 <--
PRIORITY APPLN. INFO.:			US 2002-408027P	P 20020904 <--
			US 2002-421959P	P 20021029 <--
			CN 2003-824997	A3 20030903 <--



AB The title compds. [I R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared. Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μ M and 0.029 μ M against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I is claimed. [This

abstract


record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 677786-82-2P 677787-26-7P


RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

RN 677786-82-2 CAPLUS

CN Benzamide, N-[4-[[[3-bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]methyl]phenyl]-3-phenoxy- (CA INDEX NAME)



RN 677787-26-7 CAPLUS
 CN Benzamide, N-[3-[[[3-bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]methyl]phenyl]-3-phenoxy- (CA INDEX NAME)



L6 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:41269 CAPLUS

DOCUMENT NUMBER: 140:77038

TITLE: Preparation of 3-[heteroarylmethoxy]pyridines and their analogues as p38 map kinase inhibitors

INVENTOR(S): Murray, Christopher William; Hartshorn, Michael John; Frederickson, Martyn; Congreve, Miles Stuart; Padova, Alessandro; Woodhead, Steven John; Gill, Adrian Liam; Woodhead, Andrew James

PATENT ASSIGNEE(S): Astex Technology Limited, UK

SOURCE: PCT Int. Appl., 134 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004720	A1	20040115	WO 2003-GB2864	20030703 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003246927	A1	20040123	AU 2003-246927	20030703 <--
EP 1545523	A1	20050629	EP 2003-762777	20030703 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005538975	T	20051222	JP 2004-518947	20030703 <--
US 20060063782	A1	20060323	US 2005-519922	20050103 <--
PRIORITY APPLN. INFO.:			GB 2002-15383	A 20020703 <--
			US 2002-393121P	P 20020703 <--
			GB 2002-26149	A 20021108 <--
			WO 2003-GB2864	W 20030703 <--

OTHER SOURCE(S): MARPAT 140:77038

GI



AB Title compds. I [X=Y = CR2=CR3, CR2=N; R1 = H, halo, amino, etc.; R2=3 = H, alkyl, aryl, etc.; R4 = carboaryl, heteroaryl; R5 = halo, amino, carboxamido, etc.] are prepared For instance, 2-amino-3-benzoyloxypyridine is prepared by alkylation of 2-amino-3-hydroxypyridine with benzyl chloride. A related example, 2-amino-3-[2-phenylbenzyloxy]pyridine has IC50 < 10µM for p38 map kinase. I are useful in the treatment of diseases ameliorated by inhibiting p38 MAP kinase.

IT 642085-16-3P, N-[4-Fluoro-3-(pyrazin-2-yloxymethyl)phenyl]-3-phenoxbenzamide


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-[heteroarylmethoxy]pyridines and their analogs as p38 map kinase inhibitors for treatment of arthritis)

RN 642085-16-3 CAPLUS

CN Benzamide, N-[4-fluoro-3-[(2-pyrazinyloxy)methyl]phenyl]-3-phenoxy- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:874965 CAPLUS

DOCUMENT NUMBER: 139:364958

TITLE: Preparation of omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

INVENTOR(S): Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-Katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.

PATENT ASSIGNEE(S): Bayer Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 60 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030207872	A1	20031106	US 2002-42226	20020111 <--
PRIORITY APPLN. INFO.:			US 2002-42226	20020111 <--

OTHER SOURCE(S): MARPAT 139:364958

AB Urea derivs. of formula A-NHCONH-B or pharmaceutically acceptable salts thereof [A = a substituted moiety of up to 40 carbon atoms of the formula -L-(M-L1)q; where L = a 5 or 6 membered cyclic structure bound directly to D; L1 = a substituted cyclic moiety having at least 5 members; M = a bridging group having at least one atom; q = an integer of 1-3; each cyclic structure of L and L1 contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur; B = a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur] are prepared. These compds. are useful for raf mediated diseases, in particular a cancerous cell growth mediated by raf kinase. All compds. exemplified, e.g. N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea, displayed IC50 of between 1 mM and 10 μ M.

IT 2844461-67-2P 2844461-68-3P 2844461-70-7P
2844461-71-8P 2844462-09-5P 2844462-10-8P
2844462-15-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of ω -carboxyaryl substituted di-Ph ureas as raf

kinase inhibitors for treating raf-mediated diseases
such as cancerous cell growth)


RN 284461-67-2 CAPLUS

CN Benzamide, N-(4-fluorophenyl)-3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-68-3 CAPLUS

CN Benzamide, N-[4-(dimethylamino)phenyl]-3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-70-7 CAPLUS

CN Benzamide, 3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 284461-71-8 CAPLUS


CN Benzamide, 3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-[4-(2-pyridinyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)




RN 284462-09-5 CAPLUS
 CN Benzamide, 3-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(4-fluorophenyl)-
 (CA INDEX NAME)



RN 284462-10-8 CAPLUS
 CN Benzamide, 3-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)



RN 284462-15-3 CAPLUS
 CN Benzamide, 3-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(morpholinyl)phenyl]- (CA INDEX NAME)



L6 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:757329 CAPLUS

DOCUMENT NUMBER: 139:276918

TITLE: Preparation of omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

INVENTOR(S): Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.

PATENT ASSIGNEE(S): Bayer Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 61 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030181442	A1	20030925	US 2001-993647	20011127 <--
PRIORITY APPLN. INFO.:			US 2001-993647	20011127 <--

OTHER SOURCE(S): MARPAT 139:276918

AB Aryl ureas of formula A-NHCONH-B [A = a substituted moiety of up to 40 carbon atoms of the formula: -L-(M-L1)q (where L = a 5 or 6 membered cyclic structure bound directly to D, L1 comprises a substituted cyclic moiety having at least 5 members; M = a bridging group having at least one atom; q = an integer of from 1-3; each cyclic structure of L and L1 contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur); B = a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur] are prepared. These urea derivs. are useful for treating raf mediated diseases, in particular cancerous cell growth mediated by raf kinase. Thus, N-[4-bromo-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea. Thus, a solution of 4-bromo-3-(trifluoromethyl)phenyl isocyanate (8.0 g, 30.1 mmol) in CH2Cl2 (80 mL) was added dropwise to a solution of 4-[2-(N-methylcarbamoyl)-4-pyridyloxy]aniline (7.0 g, 28.8 mmol) in CH2Cl2 (40 mL) at 0°, stirred at room temperature for 16 h, and filtered to give, after washing the yellow solids, washing with CH2Cl2 (2 + 50 mL), and drying under reduced pressure (approx. 1 mmHg) at 40° to give N-[4-bromo-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea. All compds. exemplified showed IC50 between 1 nM to 10 µM against raf kinase.


IT 284461-67-2P 284461-68-3P 284461-70-7P
284461-71-8P 284462-09-5P 284462-10-8P
284462-15-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of omega-carboxyaryl substituted di-Ph ureas as raf kinase inhibitors and anticancer agents)


RN 284461-67-2 CAPLUS

CN Benzamide, N-[4-(4-fluorophenyl)-3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-68-3 CAPLUS

CN Benzamide, N-[4-(dimethylamino)phenyl]-3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-70-7 CAPLUS

CN Benzamide, 3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 284461-71-8 CAPLUS

CN Benzamide, 3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-[4-(2-pyridinyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)




RN 284462-09-5 CAPLUS

CN Benzamide, 3-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(4-fluorophenyl)- (CA INDEX NAME)




RN 284462-10-8 CAPLUS

CN Benzamide, 3-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)



RN 284462-15-3 CAPLUS

CN Benzamide, 3-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



L6 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:590832 CAPLUS

DOCUMENT NUMBER: 139:149528

TITLE: Preparation of diphenylureas as RAF kinase inhibitors

INVENTOR(S): Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.

PATENT ASSIGNEE(S): Bayer Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 62 pp., Cont. of U. S. Ser. No. 42,203.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030144278	A1	20030731	US 2002-283248	20021030 <--
US 7235576	B1	20070626	US 2002-42203	20020111 <--
PRIORITY APPLN. INFO.:			US 2001-367380P	P 20010112 <--
			US 2002-42203	A1 20020111 <--

OTHER SOURCE(S): MARPAT 139:149528

AB ADB [I; D = NHCONH; A = L(ML)q; L = 5-6 membered cyclic structure bound directly to D; L1 = substituted cyclic moiety having ≥5 members, M = bridging group having ≥1 atom; q = 1-3; L, L1 contain 0-4 N, O, S; B = (substituted) up to tricyclic aryl, heteroaryl of ≤30 C atoms with ≥1 6-membered cyclic structure bound directly to D containing 0-4 N, O, S], were prepared Thus, 4-chloro-3-(trifluoromethyl)phenyl isocyanate in CH2Cl2 was added dropwise to a suspension of 4-[2-(N-methylcarbamoyl)-4-pyridyloxy]aniline (preparation given) in CH2Cl2 at

0°; the resulting mixture was stirred at room temperature for 22 h. to afford N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea. I inhibited RAF kinase in the range 1 nM-1 μM. I pharmaceutical compns. are claimed.


IT 284461-67-2P 284461-68-3P 284461-70-7P
284461-71-8P 284462-09-5P 284462-10-8P
284462-15-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diphenylureas as RAF kinase inhibitors)


RN 284461-67-2 CAPLUS

CN Benzamide, N-[4-(fluorophenyl)-3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-68-3 CAPLUS

CN Benzamide, N-[4-(dimethylamino)phenyl]-3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-70-7 CAPLUS

CN Benzamide, 3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 284461-71-8 CAPLUS

CN Benzamide, 3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-[4-(2-pyridinyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)




RN 284462-09-5 CAPLUS

CN Benzamide, 3-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(4-fluorophenyl)-
(CA INDEX NAME)




RN 284462-10-8 CAPLUS

CN Benzamide, 3-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)



RN 284462-15-3 CAPLUS

CN Benzamide, 3-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



L6 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:615574 CAPLUS

DOCUMENT NUMBER: 137:169425


TITLE: Preparation of N-aryl-N'-[acylphenoxy]phenylureas as
raf kinase inhibitors

INVENTOR(S): Dumas, Jacques; Riedl, Bernd; Khire, Uday; Wood, Jill E.; Sibley, Robert N.; Monahan, Mary-Katherine; Renick, Joel; Gunn, David E.; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.
 PATENT ASSIGNEE(S): Bayer Corporation, USA
 SOURCE: PCT Int. Appl., 125 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002062763	A2	20020815	WO 2002-US3361	20020207 <--
WO 2002062763	A3	20021010		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20020165394	A1	20021107	US 2001-777920	20010207 <--
AU 2002238042	A1	20020819	AU 2002-238042	20020207 <--
AU 2004200722	A1	20040318	AU 2004-200722	20040224 <--
AU 2004200722	B2	20080110		

PRIORITY APPLN. INFO.:
 US 2001-777920 A 20010207 <--
 US 1999-115877P P 19990113 <--
 US 1999-257266 B2 19990225 <--
 US 1999-425228 B2 19991022 <--
 AU 2000-25016 A3 20000112 <--
 US 2001-758548 A2 20010112 <--
 WO 2002-US3361 W 20020207 <--

OTHER SOURCE(S): MARPAT 137:169425
 GI



II

AB Title compds., e.g., RNHCONHZOR1 [I; R = C6H4(CMe3)-3, 2-methoxy-5-trifluoromethylphenyl, 4-chloro-3-trifluoromethylphenyl, 2-methoxy-3-quinolyl, etc.; R1 = (un)substituted acylphenyl, -acylpyridinyl, etc.; Z = (un)substituted 1,3- or -1,4-phenylene] were prepared. Thus, 4-(H2N)C6H4OC6H4(CONHMe)-4 (preparation given) was condensed with 3-(Me3C)C6H4NH2 and CO(OCCl3)2 to give title compound II. Data for biol. activity of title compds. were given.
 IT 284461-67-2P 284461-68-3P 284461-70-7P

284461-71-8P 284462-09-5P 284462-10-8P


284462-15-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-aryl-N'-[(acylphenoxy)phenyl]ureas as raf kinase inhibitors)


RN 284461-67-2 CAPLUS

CN Benzamide, N-[4-(fluorophenyl)-3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-68-3 CAPLUS

CN Benzamide, N-[4-(dimethylamino)phenyl)-3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-70-7 CAPLUS

CN Benzamide, 3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 284461-71-8 CAPLUS

CN Benzamide, 3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-[4-(2-pyridinyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)




RN 284462-09-5 CAPLUS

CN Benzamide, 3-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(4-fluorophenyl)-
(CA INDEX NAME)




RN 284462-10-8 CAPLUS

CN Benzamide, 3-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)



RN 284462-15-3 CAPLUS

CN Benzamide, 3-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 21 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:545674 CAPLUS

DOCUMENT NUMBER: 135:137516

TITLE: Synthesis of heteroarylbenzamides and analogs used for inhibiting protein kinases

INVENTOR(S): Bender, Steven Lee; Bhumraikar, Dilip; Collins, Michael Raymond; Cripps, Stephan James; Deal, Judith Gail; Nambu, Mitchell David; Palmer, Cynthia Louise; Peng, Zhengwei; Varney, Michael David; Jia, Lei

PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 237 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001053274	A1	20010726	WO 2001-US1723	20010119 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2394703	A1	20010726	CA 2001-2394703	20010119 <--
US 20020103203	A1	20020801	US 2001-764306	20010119 <--
US 6635641	B2	20031021		
EP 1252146	A1	20021030	EP 2001-906592	20010119 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001008025	A	20021105	BR 2001-8025	20010119 <--
JP 2003529558	T	20031007	JP 2001-553276	20010119 <--
MX 2002PA07102	A	20030128	MX 2002-PA7102	20020719 <--
US 20040092747	A1	20040513	US 2003-621979	20030717 <--
PRIORITY APPLN. INFO.:				
			US 2000-177059P	P 20000121 <--
			US 2001-764306	A3 20010119 <--
			WO 2001-US1723	W 20010119 <--
OTHER SOURCE(S): MARPAT 135:137516				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Z = CH, NH; Q = moiety such that ring A is (un)substituted mono- or bicyclic heteroaryl which has at least 2 carbon atoms in the heteroaryl ring system; X = CH₂, O, S, NH; Y = CH₂, O, S, provided at least one of X and Y = CH₂ or X and Y form a cyclopropyl ring; R₂-3 = H, Me, halo, CF₃, CN; R₄ = CONHR₅, NHCOR₆; where R₅ = (un)substituted aryl, heteroaryl, cycloalkyl, etc.; R₆ = (un)substituted aryl, heteroaryl, cycloalkyl, etc.] are prepared. Examples include synthetic procedures for over 150 compds., 11 biol. assays and 3 sample formulations. For instance, 3-mercaptobenzoic acid was treated with α-chloro-N-methoxy-N-methylacetamide followed by carbodiimide coupling to 2-methyl-6-aminoquinoline to give II. II was converted to a β-thiono-ketone with thioacetanilide/n-BuLi followed by treatment with hydrazine to give pyrazole III. III gave 85% inhibition of an lck protein tyrosine kinase at 5 μM and had Ki = 2.21 nM for VEGF-R2A50. Treatment of cancer as well as other disease states

associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis are claimed uses of the invention.

IT 351323-37-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (synthesis of heteroarylbenzamides used for inhibiting protein kinases)
 RN 351323-37-0 CAPLUS
 CN Benzamide, 3-phenoxy-N-[3-[(1H-pyrazolo[3,4-d]pyrimidin-4-ylthio)methyl]phenyl]- (CA INDEX NAME)






REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2000:772609 CAPLUS
 DOCUMENT NUMBER: 133:335157
 TITLE: Benzopyrrolone derivatives and related compounds as inhibitors of c-jun n-terminal kinases (JNK)
 INVENTOR(S): Salituro, Francesco Gerald; Bemis, Guy W.; Wilke, Susanne; Green, Jeremy; Cao, Jingrong; Gao, Hui; Harrington, Edmund Martin
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
 SOURCE: PCT Int. Appl., 138 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000064872	A1	20001102	WO 2000-US10866	20000421 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1175399	A1	20020130	EP 2000-926272	20000421 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			


IE, SI, LT, LV, FI, RO
 US 20030153560 A1 20030814 US 2001-35823 20011023 <--
 US 20080033022 A1 20080207 US 2007-729420 20070328 <--
 PRIORITY APPLN. INFO.: US 1999-130752P P 19990423 <--
 WO 2000-US10866 W 20000421 <--
 US 2001-35823 B1 20011023 <--
 OTHER SOURCE(S): MARPAT 133:335157
 GI



AB Benzopyrrolone derivs. and related compds. I (T = N or CR1; U = N or CR2; V = N or CR3; X = N or CR4; Y = CH2Q1, COQ1, CONHQ1, CO2Q1, SO2Q1 or SO2NHQ1 [where Q1 = (un)substituted C1-6alkyl, C1-6alkenyl, (non)aromatic 5-7 membered ring or 9-14 membered bicyclic or tricyclic (non)aromatic carbocyclic or heterocyclic ring system]; W = N or C [wherein when W = N, R8 = lone pair of electrons and when W = C, R8 = R7]; R1 = NHR5, OR5, SR5, R5 {R5 = H, N(R)2, NHOH, NO2, CO2R, halo, (un)substituted C1-6alkyl, C1-6alkenyl, (non)aromatic 5-7 membered ring or 9-14 membered bicyclic or tricyclic (non)aromatic carbocyclic or heterocyclic ring system [R = C1-6alkyl, C1-6alkenyl, (non)aromatic 5-7 membered ring or 9-10 membered bicyclic (non)aromatic carbocyclic or heterocyclic ring system]}; R2, R3 or R4 = CONH2, CONHR, CON(R)2, NHR5, NHCH2R5, OR5, SR5, etc.; R7 = H, C1-6alkyl, C1-6alkenyl, (non)aromatic 5-7 membered ring or 9-14 membered bicyclic (non)aromatic carbocyclic or heterocyclic ring system) and II (Z = CH or N) or a pharmaceutically acceptable derivative or prodrug thereof, are disclosed as inhibitors of JNK, a mammalian protein kinase involved in cell proliferation, cell death, and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. Thus, benzopyrrolone III was prepared in seven steps with pyrrolone ring formation via reductive cyclization. The invention also provides pharmaceutical compns. comprising the inhibitors of the invention and methods of utilizing those compns. in the treatment and prevention of various disorders, e.g., inflammatory diseases, autoimmune diseases,

destructive bone disorders, proliferative disorders and neurodegenerative diseases. Exemplary compds. I had Ki values of < 1 μ M for inhibition of JNK3 in vitro.

IT 303743-18-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn of benzopyrrolone derivs. and related compds. as inhibitors of c-jun n-terminal kinases (JNK))
 RN 303743-18-2 CAPLUS
 CN Benzamide, N-[1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-2,3-dihydro-3-(hydroxyimino)-2-oxo-1H-indol-6-yl]-3-phenoxy- (CA INDEX NAME)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 23 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:493516 CAPLUS

DOCUMENT NUMBER: 133:120157

TITLE: Preparation of α -carboxy(hetero)aryl substituted diphenyl ureas as raf kinase inhibitors

INVENTOR(S): Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-Katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.

PATENT ASSIGNEE(S): Bayer Corporation, USA
 SOURCE: PCT Int. Appl., 120 pp.
 CODEN: PIXXD2


DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000042012	A1	20000720	WO 2000-US648	20000112 <--
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2359510	A1	20000720	CA 2000-2359510	20000112 <--
CA 2359510	C	20070213		

CA 2549558	A1	20000720	CA 2000-2549558	20000112 <--
AU 2000025016	A	20000801	AU 2000-25016	20000112 <--
EP 1140840	A1	20011010	EP 2000-903239	20000112 <--
EP 1140840	B1	20060322		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
EE 200100368	A	20030415	EE 2001-368	20000112 <--
EE 4913	B1	20071015		
HU 2003000866	A2	20030728	HU 2003-866	20000112 <--
HU 2003000866	A3	20060428		
HU 225780	B1	20070828		
JP 2003526613	T	20030909	JP 2000-593580	20000112 <--
JP 3845792	B2	20061115		
BR 2000007487	A	20030923	BR 2000-7487	20000112 <--
CN 1219764	C	20050921	CN 2000-802685	20000112 <--
CN 1721397	A	20060118	CN 2005-10089504	20000112 <--
AT 321027	T	20060415	AT 2000-903239	20000112 <--
PT 1140840	T	20060531	PT 2000-903239	20000112 <--
ES 2255971	T3	20060716	ES 2000-903239	20000112 <--
EP 1690853	A1	20060816	EP 2005-28442	20000112 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
SK 285532	B6	20070301	SK 2001-988	20000112 <--
RU 2319693	C2	20080320	RU 2001-122818	20000112 <--
CZ 299125	B6	20080430	CZ 2001-2489	20000112 <--
TW 269791	B	20070101	TW 2000-89100575	20000407 <--
US 20010011135	A1	20010802	US 2001-773659	20010202 <--
US 20010011136	A1	20010802	US 2001-773675	20010202 <--
US 20010016659	A1	20010823	US 2001-773672	20010202 <--
US 20010027202	A1	20011004	US 2001-773658	20010202 <--
US 20010034447	A1	20011025	US 2001-773604	20010202 <--
IN 2001MN00799	A	20050304	IN 2001-MN799	20010705 <--
NO 2001003463	A	20010912	NO 2001-3463	20010712 <--
NO 321059	B1	20060306		
MX 2001PA07118	A	20021023	MX 2001-PA7118	20010712 <--
ZA 2001005751	A	20030714	ZA 2001-5751	20010712 <--
US 20020137774	A1	20020926	US 2001-907970	20010719 <--
BG 105763	A	20020329	BG 2001-105763	20010801 <--
BG 65158	B1	20070430		
BG 109688	A	20070531	BG 2001-109688	20010801 <--
HR 2001000580	A1	20020831	HR 2001-580	20010802 <--
US 20020042517	A1	20020411	US 2001-948915	20010910 <--
US 7351834	B1	20080401	US 2002-889227	20020108 <--
US 20030139605	A1	20030724	US 2002-71248	20020211 <--
HK 1045504	A1	20060407	HK 2002-106872	20020920 <--
AU 2004200722	A1	20040318	AU 2004-200722	20040224 <--
AU 2004200722	B2	20080110		
NO 2005005863	A	20010912	NO 2005-5863	20051209 <--
JP 2006328075	A	20061207	JP 2006-190034	20060711 <--
KR 2007020158	A	20070216	KR 2007-702656	20070201 <--
US 20080032979	A1	20080207	US 2007-845595	20070827 <--
IN 2007MN01633	A	20071214	IN 2007-MN1633	20071005 <--
US 20080153823	A1	20080626	US 2007-956111	20071213 <--
PRIORITY APPLN. INFO.:				
			US 1999-115877P	P 19990113 <--
			US 1999-257266	A2 19990225 <--
			US 1999-425228	A2 19991022 <--
			US 1999-115878P	P 19990113 <--
			AU 2000-25016	A3 20000112 <--
			CA 2000-2359510	A3 20000112 <--
			CN 2000-802685	A3 20000112 <--
			EP 2000-903239	A3 20000112 <--
			JP 2000-593580	A3 20000112 <--

WO 2000-US648	W 20000112 <--
IN 2001-MN799	A3 20010705 <--
KR 2001-708847	A3 20010712 <--
US 2001-948915	A1 20010910 <--
US 2002-889227	A1 20020108 <--

OTHER SOURCE(S): MARPAT 133:120157
GI




AB This invention relates to the preparation and use of (hetero)aryl ureas ANHCONHB [I; A = L(MLl)q; L = 5- or 6-membered (hetero)aryl, especially Ph or pyridinyl; M = bridging group; Ll = (hetero)aryl with at least one (un)substituted sulfamoyl, carboxy, or carbamoyl substituent; q = 1-3; B = certain (un)substituted mono- to tricyclic aryl or heteroaryl groups] for the treatment of raf mediated diseases, such as cancer (no data). Approx. 100 invention compds. and numerous intermediates were prepared For instance, 3-tert-butylaniline was coupled with bis(trichloromethyl)carbonate to form the isocyanate, followed by addition of 4-(3-N-methylcarbamoylphenoxy)aniline (preparation given) to afford the urea II.

IT 284461-67-2P 284461-68-3P 284461-70-7P
284461-71-8P 284462-09-5P 284462-10-8P
284462-15-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of *o*-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)


RN 284461-67-2 CAPLUS

CN Benzamide, N-(4-(dimethylamino)phenyl)-3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-68-3 CAPLUS

CN Benzamide, N-(4-(dimethylamino)phenyl)-3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-70-7 CAPLUS

CN Benzamide, 3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 284461-71-8 CAPLUS

CN Benzamide, 3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-[4-(2-pyridinyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)




RN 284462-09-5 CAPLUS

CN Benzamide, 3-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(4-fluorophenyl)- (CA INDEX NAME)




RN 284462-10-8 CAPLUS

CN Benzamide, 3-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)



RN 284462-15-3 CAPLUS

CN Benzamide, 3-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:493376 CAPLUS

DOCUMENT NUMBER: 133:120155

TITLE: Preparation of ω -carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors

INVENTOR(S): Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-Katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.

PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: PCT Int. Appl., 148 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000041698	A1	20000720	WO 2000-US768	20000113 <--
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2359244	A1	20000720	CA 2000-2359244	20000113 <--
EP 1158985	A1	20011205	EP 2000-905597	20000113 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

IE, SI, LT, LV, FI, RO				
MX 2001PA07120	A	20011101	MX 2001-PA7120	20010712 <--
US 20030139605	A1	20030724	US 2002-71248	20020211 <--
US 20030105091	A1	20030605	US 2002-86417	20020304 <--
AU 2004200566	A1	20040311	AU 2004-200566	20040213 <--
AU 2004200566	B2	20060817		
AU 2004200722	A1	20040318	AU 2004-200722	20040224 <--
AU 2004200722	B2	20080110		
US 20080027061	A1	20080131	US 2007-845597	20070827 <--
PRIORITY APPLN. INFO.:			US 1999-115878P	P 19990113 <--
			US 1999-257265	A2 19990225 <--
			US 1999-425229	A2 19991022 <--
			US 1999-115877P	P 19990113 <--
			US 1999-257266	B2 19990225 <--
			US 1999-425228	B1 19991022 <--
			AU 2000-25016	A3 20000112 <--
			AU 2000-27250	A3 20000113 <--
			WO 2000-US768	W 20000113 <--
			US 2001-948915	A1 20010910 <--
			US 2002-86417	B3 20020304 <--

OTHER SOURCE(S): MARPAT 133:120155

GI



AB The title compds. ADB [I; D = NHCONH; A = substituted moiety of up to 40 carbon atoms of the formula L(ML1)q (wherein L = 5-6 membered cyclic structure; L1 = substituted cyclic moiety having at least 5 members; M = bridging group having at least one atom; q = 1-3; each of L and L1 contains 0-4 members of the group consisting of N, O and S); B = (un)substituted up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D containing 0-4 members of the group consisting of N, O and S), useful in treating p38 mediated diseases, were prepared. E.g., a multi-step synthesis of the urea II which showed IC50 of 1-10 μ M against p38, was given.


Compds. I are effective at 0.01-200 mg/kg/day (oral administration).

IT 284461-67-2P 284461-68-3P 284461-70-7P
284461-71-8P 284462-09-5P 284462-10-8P
284462-15-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of α -carboxy aryl substituted di-Ph ureas as p38 kinase inhibitors)


RN 284461-67-2 CAPLUS

CN Benzamide, N-(4-fluorophenyl)-3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-68-3 CAPLUS

CN Benamide, N-[4-(dimethylamino)phenyl]-3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284461-70-7 CAPLUS

CN Benamide, 3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 284461-71-8 CAPLUS

CN Benamide, 3-[4-[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-[4-(2-pyridinyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)




RN 284462-09-5 CAPLUS


CN Benamide, 3-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(4-fluorophenyl)- (CA INDEX NAME)



RN 284462-10-8 CAPLUS
 CN Benzamide, 3-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]phenoxy]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)



RN 284462-15-3 CAPLUS
 CN Benzamide, 3-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1999:753201 CAPLUS
 DOCUMENT NUMBER: 131:351089
 TITLE: Preparation of N-[(arylcarbonylamino)phenyl]benzamides and analogs as p38 kinase inhibitors
 INVENTOR(S): Brown, Dearg Sutherland; Brown, George Robert
 PATENT ASSIGNEE(S): Zeneca Limited, UK
 SOURCE: PCT Int. Appl., 158 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9959959	A1	19991125	WO 1999-GB1489	19990511 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,				

MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
 TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2328927 A1 19991125 CA 1999-2328927 19990511 <--
 CA 2328927 C 20080219
 AU 9939399 A 19991206 AU 1999-39399 19990511 <--
 AU 749293 B2 20020620
 BR 9910474 A 20010102 BR 1999-10474 19990511 <--
 EP 1077931 A1 20010228 EP 1999-922290 19990511 <--
 EP 1077931 B1 20041117

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO


TR 200003353 T2 20010420 TR 2000-3353 19990511 <--
 HU 2001002295 A2 20011128 HU 2001-2295 19990511 <--
 HU 2001002295 A3 20021128
 JP 2002515476 T 20020528 JP 2000-549578 19990511 <--
 NZ 507144 A 20021025 NZ 1999-507144 19990511 <--
 RU 2215736 C2 20031110 RU 2000-131611 19990511 <--
 AT 282590 T 20041215 AT 1999-922290 19990511 <--
 CN 1185211 C 20050119 CN 1999-806143 19990511 <--
 PT 1077931 T 20050331 PT 1999-922290 19990511 <--
 ES 2232137 T3 20050516 ES 1999-922290 19990511 <--
 PL 195600 B1 20071031 PL 1999-344164 19990511 <--
 SK 286123 B6 20080407 SK 2000-1718 19990511 <--
 IN 2000MN00475 A 20050715 IN 2000-MN475 20001006 <--
 MX 2000PA10432 A 20010419 MX 2000-PA10432 20001024 <--
 ZA 2000006030 A 20020125 ZA 2000-6030 20001025 <--
 US 6579872 B1 20030617 US 2000-674560 20001102 <--
 NO 2000005767 A 20001114 NO 2000-5767 20001114 <--
 HK 1033754 A1 20050506 HK 2001-104301 20010620 <--
 US 20030212068 A1 20031113 US 2003-424127 20030428 <--
 US 6956037 B2 20051018
 IN 2004DE01130 A 20070112 IN 2004-DE1130 20040615 <--
 IN 2004MN00348 A 20050429 IN 2004-MN348 20040618 <--

PRIORITY APPLN. INFO.:

GB 1998-10357 A 19980515 <--
 GB 1998-22483 A 19981016 <--
 WO 1999-GB1489 W 19990511 <--
 IN 2000-MN475 A3 20001006 <--
 US 2000-674560 A3 20001102 <--

OTHER SOURCE(S): MARPAT 131:351089


GI




II

AB R1CONHNHCO(CH2)qR4 [I; R1 = (un)substituted Ph; R4 = (un)substituted cycloalkyl or -aryl; Z = (un)substituted 6-alkyl-1,3-phenylene or -6-halo-1,3-phenylene; q = 0-4] were prepared. Thus, 2-methyl-5-nitroaniline was amidated by 3,4-(MeO)C6H3COCl and the reduced product amidated by 3-(O2N)C6H4COCl to give, after reduction and MeSO2Cl treatment, title compound II. Data for biol. activity of select I were given.


IT 250680-86-5P 250680-90-1P 250681-16-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-[(arylcarbonylamino)phenyl]benzamides and analogs as p38 kinase inhibitors)
 RN 250680-86-5 CAPLUS
 CN Benzamide, N-[3-[[4-[(diethylamino)methyl]benzoyl]amino]-4-methylphenyl]-3-phenoxy- (CA INDEX NAME)



RN 250680-90-1 CAPLUS
 CN Benzamide, N-[4-methyl-3-[[3-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]phenyl]-3-phenoxy- (CA INDEX NAME)



RN 250681-16-4 CAPLUS
 CN Benzamide, N-[3-[[3-[(6-chloro-4-pyrimidinyl)oxy]benzoyl]amino]-4-methylphenyl]-3-(4-morpholinyl)- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 26 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:425745 CAPLUS

DOCUMENT NUMBER: 131:87909

TITLE: Inhibition of p38 kinase activity using substituted heterocyclic ureas

INVENTOR(S): Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Paulsen, Holger; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Hatoum-Mokdad, Holia; Johnson, Jeffrey; Lee, Wendy; Redman, Aniko

PATENT ASSIGNEE(S): Bayer Corporation, USA

SOURCE: PCT Int. Appl., 126 pp.


CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932111	A1	19990701	WO 1998-US26080	19981222 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2315720	A1	19990701	CA 1998-2315720	19981222 <--
AU 9919971	A	19990712	AU 1999-19971	19981222 <--
AU 739642	B2	20011018		
EP 1041982	A1	20001011	EP 1998-964709	19981222 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001526223	T	20011218	JP 2000-525102	19981222 <--
MX 2000PA06233	A	20020918	MX 2000-PA6233	20000622 <--
PRIORITY APPLN. INFO.:			US 1997-995750	19971222 <--
			WO 1998-US26080	W 19981222 <--
OTHER SOURCE(S):		MARPAT 131:87909		
GI				




AB A method for treatment of p38-mediated disease other than cancer comprises administration of ANHCONHB [I; A = substituted isoxazolyl, pyrazolyl, thienyl, furyl; B = (substituted) mono-, di-, or tricyclic aryl, heteroaryl containing ≥ 1 5-6 membered aromatic structure containing 0-4 N, O, or S atoms]. Reaction of 4-(4-pyridinylthio)aniline with 3-tert-butyl-5-isoxazolyl isocyanate in toluene gave title compound II. In an in vitro p38 kinase assay, I displayed IC50 values of 1-10 μ M.

IT 228999-76-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted heterocyclic ureas for treatment of p38 kinase-mediated diseases other than cancer)

RN 228999-76-6 CAPLUS

CN Benzamide, 3-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:425740 CAPLUS

DOCUMENT NUMBER: 131:73648

TITLE: Inhibition of raf kinase using substituted heterocyclic ureas

INVENTOR(S): Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Paulsen, Holger; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Hatoum-Mokdad, Holia; Johnson, Jeffrey; Lee, Wendy; Redman, Aniko

PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: PCT Int. Appl., 163 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932106	A1	19990701	WO 1998-US26078	19981222 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2315717	A1	19990701	CA 1998-2315717	19981222 <--
AU 9921989	A	19990712	AU 1999-21989	19981222 <--
EP 1047418	A1	20001102	EP 1998-965981	19981222 <--
EP 1047418	B1	20050727		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200002618	T2	20010420	TR 2000-2618	19981222 <--
JP 2001526220	T	20011218	JP 2000-525097	19981222 <--
HU 2001001704	A2	20011228	HU 2001-1704	19981222 <--
HU 2001001704	A3	20021228		
BR 9814374	A	20020514	BR 1998-14374	19981222 <--
CN 1149085	C	20040512	CN 1998-813623	19981222 <--
RU 2232015	C2	20040710	RU 2000-120184	19981222 <--
CN 1544420	A	20041110	CN 2004-10028655	19981222 <--
CN 100360507	C	20080109		
AT 300299	T	20050815	AT 1998-965981	19981222 <--
ES 2153340	T3	20060201	ES 1998-965981	19981222 <--
SK 286213	B6	20080506	SK 2000-963	19981222 <--
CZ 299156	B6	20080507	CZ 2000-2350	19981222 <--
NO 2000003232	A	20000821	NO 2000-3232	20000621 <--
NO 326150	B1	20081006		

MX 2000PA06226	A	20020311	MX 2000-PA6226	20000622 <--
IN 193672	A1	20040731	IN 2000-MN153	20000704 <--
BG 104597	A	20010228	BG 2000-104597	20000712 <--
BG 64984	B1	20061130		
HK 1029052	A1	20051118	HK 2000-107684	20001130 <--
AU 2003204708	A1	20030717	AU 2003-204708	20030613 <--
AU 2003204708	B2	20060525		
IN 2003MN00990	A	20050429	IN 2003-MN990	20031024 <--
PRIORITY APPLN. INFO.:			US 1997-996343	A 19971222 <--
			AU 1999-21989	A3 19981222 <--
			WO 1998-US26078	W 19981222 <--

OTHER SOURCE(S): MARPAT 131:73648
GI




AB A method for treatment of cancerous cell growth mediated by raf kinase comprises administration of urea derivs. ANHCONHB [I; A = substituted isoxazolyl, thienyl, thiadiazolyl, furyl, pyrazolyl, etc.; B = (substituted) mono-, di-, or tricyclic aryl, heteroaryl containing ≥ 1 5-6 membered aromatic structure containing 0-4 N, O, or S atoms]. Reaction of 4-phenoxyphenyl isocyanate with 5-amino-3-tert-butylisoxazole in methylene chloride and heating at reflux temperature for 2 days gave title compound II. In an in vitro raf kinase assay, I displayed IC₅₀ values of 1-10 μ M.

IT 228999-76-6P 229000-21-9P 229000-25-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted heterocyclic ureas for treatment of cancerous cell growth mediated by raf kinase)


RN 228999-76-6 CAPLUS

CN Benzamide, 3-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-phenyl- (CA INDEX NAME)




RN 229000-21-9 CAPLUS

CN Benzamide, 3-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-(4-fluorophenyl)- (CA INDEX NAME)



RN 229000-25-3 CAPLUS
 CN Benzamide, 3-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY SESSION

FULL ESTIMATED COST

154.28 340.38

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE TOTAL

ENTRY SESSION

CA SUBSCRIBER PRICE

-22.14 -22.14

STN INTERNATIONAL LOGOFF AT 12:14:10 ON 07 JAN 2009